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ABSTRACT	CHARACTERIZATION	OF	HIGHLY	HETEROGENEOUS	HEPARIN-PROTEIN	COMPLEXES	USING	NOVEL	MASS	SPECTROMETRY-BASED	APPROACHES	SEPTEMBER	2017	YUNLONG	ZHAO,	B.S.,	NANKAI	UNIVERSITY	Ph.D.,	UNIVERSITY	OF	MASSACHUSETTS	AMHERST	Directed	by:	Professor	Igor	A.	Kaltashov	
	Heparin-like	glycosaminoglycan	(GAG)	is	a	family	of	polysaccharide	involved	in	variety	 of	 physiological	 processes.	 They	 have	 potentials	 to	 interact	 with	 a	 broad	range	 of	 proteins	 and	 many	 of	 them	 hold	 crucial	 values	 in	 regulation	 of	 protein	functions.	My	dissertation	addresses	 the	significance	and	challenges	 in	 the	 field	of	heparin-mediated	studies,	with	a	focus	on	the	questions	in	biological	and	analytical	aspects,	 which	 are	 largely	 hindered	 by	 the	 structural	 heterogeneity	 and	 function	diversity	of	heparin.	My	dissertation	reports	the	efforts	I	made	in	the	past	few	years	with	 respect	 to	 the	 development	 of	 novel	 analytical	 strategies	 based	 on	 a	combination	 of	 mass	 spectrometry,	 ion-mobility,	 gas-phase	 chemistry	 and	chromatography,	 with	 success	 in	 characterizing	 protein-GAG	 interacting	stoichiometry	and	deciphering	the	structural	code	related	to	protein-GAG	affinity.					
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CHAPTER	1		
HEPARIN-INOVOLED	RESEARCH	OBJECTIVES	AND	BACKGROUND	
1.1	Heparin	and	Heparin-Related	Scientific	Questions	
1.1.1	Structure	and	Functions	of	Heparin-Like	Glycosaminoglycan	Glycosaminoglycan	 is	 a	 big	 family	 of	 linear	 polysaccharide	 featured	 by	repetitive	units	containing	amino	sugar	and	uronic	acid	sugar.	Heparin	and	heparan	sulfate	both	belongs	to	the	same	“genus”	in	glycosaminoglycan	(GAG)	family,	which	are	ubiquitously	 found	in	human	body.	 I	borrow	the	term	from	taxonomy	because	both	heparin	and	heparan	sulfate	have	high	similarity	in	terms	of	the	structure	and	physical	properties.	The	repetitive	disaccharide	unit	of	heparin	or	heparan	sulfate	consists	of	a	glucosamine	and	a	glucuronic	acid	or	iduronic	acid	(which	differ	from	each	other	with	respect	to	the	chirality	of	C5)	(Figure	1-1).	Sequence	polydispersity	arises	from	the	biosynthesis	of	heparin-like	GAGs,	in	which	enzymatically	controlled	modifications	of	precursor	linear	polysaccharides	lead	to	tremendous	variability	in	the	 levels	 and	 patterns	 of	 O-	 and	 N-sulfation	 and	 deacetylation.	 Interestingly,	although	we	believe	these	two	species	of	GAG	can	do	exactly	the	same	thing	in	the	human	 body	 because	 they	 can	 interact	with	 broad	 range	 of	 proteins	 through	 the	sulfate	 groups	 and	 the	 basic	 groups	 in	 proteins,	 they	 actually	 have	 very	 different	physiology-relevant	emphases.	Heparan	sulfate	is	synthesized	in	many	cells	and	has	diverse	 functions	 in	 physiology	 ranging	 from	 tissue	 development	 to	 immune	regulation1,2	 and	 is	 associated	 with	 many	 diseases	 such	 as	 cancer3	 and	neurodegenerative	 diseases4,5.	 For	 example,	 matured	 fibroblast	 cells	 present	
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heparan	sulfate	in	the	form	of	proteoglycans	on	the	extracellular	matrix	and	it	can	regulate	 the	 function	 of	 fibroblast	 growth	 factor	 family,	 facilitating	 the	 affinity	 to	fibroblast	growth	factor	receptors6,7.	In	contrast,	heparin	is	only	synthesized	in	the	mast	cells,	so	it	dominantly	serves	in	blood	as	a	coagulant	regulator8-11.	Therefore,	heparan	 sulfate	has	 larger	 variety	of	 the	 chain	 lengths	 (for	 anchoring	with	matrix	proteins);	and	heparin	contains	higher	degrees	of	sulfation	(for	effective	action	on	coagulant	factors).	It	needs	to	be	clarified	here	that	we	often	use	the	term	“heparin”	to	 represent	 all	 heparin-like	 GAGs	 or	 use	 the	 heparin	 molecules	 of	 higher	modification	variety	(which	is	cheaper	as	well)	as	a	model	molecule	for	developing	analytical	 methods	 that	 can	 be	 applied	 for	 other	 heparin-like	 GAGs	 or	 other	heterogeneous	polyanions.	
1.1.2	Heparin-Like	GAG	as	Therapeutic	and	Medication	
1.1.2.1	Heparin	as	Anticoagulant	Reagents	Since	the	mystery	among	heparin,	antithrombin	and	factor	Xa	has	gradually	been	 unveiled,	 heparin	 became	 one	 of	 the	 most	 effective	 anticoagulant	 reagents	used	 for	 treatment	 of	 thrombosis	 or	 supplied	 in	 the	 circumstance	 when	 blood	clotting	needs	to	be	prevented,	such	as	surgical	operations	or	intravenous	therapies.	Although	 heparin	 as	 an	 conventional	 active	 pharmaceutical	 ingredient	 (API)	 has	been	 used	 for	 decades,	 the	 downstream	 demand	 of	 it	 is	 still	 growing.12	 Effective	heparin-based	 therapeutics	 includes	 full-length	 unfractionated	 heparin	 (UFH),	 the	enzymatic	 degraded	 low-molecular-weight	 heparin	 (LMWH)	 and	 the	 synthetic	pentasaccharides	 designed	 (commercially	 available	 as	 ArixtraTM)	 with	 different	
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efficacy	and	safety	based	on	clinical	data13-17.	The	coagulant	cascade	is	 initiated	by	activation	 of	 coagulant	 factors	 via	 proenzyme	 cleavage	 and	 terminated	 by	interaction	with	antithrombin	(AT),	an	inhibitor	to	many	coagulant	factors	(such	as	thrombin	 or	 factor	 Xa).	 The	 presence	 of	 heparin	 will	 dramatically	 facilitate	 the	inhibitory	 function	 of	 AT.	 The	 mechanism	 of	 the	 heparin-mediated	 factor	 Xa	 or	thrombin	inhibition	is	still	embroiled	in	a	controversy	between	structural	biologists	and	 biophysicists.	 From	 the	 prospective	 of	 structural	 biology,	 heparin	 binding	allosterically	 induces	 the	 conformational	 change	 of	 AT,	making	 its	 inhibitory	 loop	accessible	to	factor	Xa/thrombin,	followed	by	a	typical	serpin-protease	mechanism.	This	 point	 is	 supported	 by	 X-ray	 studies	 and	will	 be	 illustrated	 in	more	 detail	 in	section	 2.1.	 And	 biophysicists	 highlight	 the	 role	 of	 heparin	 as	 a	 bridge	 to	 either	stabilize	 the	 transient	 complex	 formed	by	AT	 and	 factor	 Xa/thrombin	 or	 improve	the	 chance	 of	 collision	 between	 the	 two	 proteins	 by	 reducing	 the	 degree	 of	diffusional	freedom.		Regardless	 of	 which	 mechanism	 is	 accepted,	 it	 has	 been	 established	 that	there	 is	positive	 relevance	between	heparin-binding	affinity	and	 the	anticoagulant	effects.	 And	 the	 binding	 affinity	 of	 heparin	 to	 proteins	 under	 physiological	conditions	 (i.e.	 neutral	 pH	 and	modest	 ionic	 strength)	 is	 affected	by	many	 factors	including	the	length	of	heparinoids	and	the	degree	of	sulfation.	Although	it	is	still	a	question	 that	 whether	 all	 heparin-binding	 proteins	 require	 a	 heparin	 motif	consisting	 in	 a	 specific	 sulfation	 pattern	 (assuming	 some	 of	 interactions	may	 just	rely	on	a	non-specific	electrostatic	interaction),	for	AT	a	particular	sulfation	pattern	within	the	binding	region	is	definitely	required	for	retrieving	the	maximum	binding	
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affinity.	Relevant	studies	have	shown	that	a	special	3-O-sulfation	at	one	glucosamine	unit	 are	 critical	 to	 modulating	 the	 binding	 affinity18,19	 but	 its	 presence	 is	 rare	 in	naturally-occurring	heparin	samples,	which	dominantly	consist	of	glucosamine	with	6-O-sulfation,	2-N-sulfation	and	iduronic	acid	with	2-O-sulfation.	That	explains	why	only	30%	of	heparin	can	bind	to	AT	and	no	AT-binding	affinity	has	been	observed	in	heparan	 sulfate,	 the	 latter	 containing	 even	 fewer	 sulfation	 sites.	 The	 synthetic	strategy	 to	 produce	 the	 heparin	 oligosaccharides	 with	 unique	 structure	 and	sequence	 (e.g.	 the	 pentasaccharide)	 has	 been	 carried	 on	 to	 generate	 species	with	high	anticoagulant	efficacy.20-22		
1.1.2.2	Heparin-Based	Therapeutics	Deliver	System	Although	the	function	and	therapeutic	value	of	heparin	mainly	resides	in	the	anticoagulant	effect	through	interaction	with	AT,	many	other	proteins	with	clinical	values	 have	 the	 potential	 to	 bind	 to	 heparin.	 Taking	 advantage	 of	 the	 functional	diversity	of	heparan	sulfate	and	synthetic	chemistry,	we	can	always	design	and	build	heparin-based	 materials	 to	 trap	 therapeutic	 proteins	 or	 nucleic	 acids.	 Heparin-based	 delivery	 systems	 feature	 high	 capacity	 of	 client	 protein	 and	 excellent	degradability.	 One	 important	 area	 where	 a	 heparin-based	 delivery	 system	 holds	enormous	promise	is	in	regenerative	medicine,	where	their	potential	for	controlled	growth	factor	delivery	is	being	actively	explored.23-25	One	of	the	possible	designs	of	a	 nanogel	 is	 to	 utilize	 heparin	 chains	 electrostatically	 attached	 to	 polycationic	segments	of	elastin-like	polypeptide	for	loading	of	growth	factors	and	morphogens	with	 subsequent	 delivery	 to	 the	 damaged	 tissue	 (such	 as	 the	 poly-
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lysine/heparin/payload	 protein	 complex	 highlighted	 in	 Figure	 1-2).	 In	 addition,	understanding	 the	 ability	 of	 heparin-like	 GAGs	 to	 sequester	 and	 release	 growth	factors	will	 translate	 to	 advances	 in	 the	design	of	 tissue	 engineering	 scaffolds.	On	the	 other	 hand,	 developing	 novel	 heparin-based	 nanomaterials	 with	 advanced	properties	 (such	 as	 temperature-sensitive	 control)	 expands	 the	 applications	 of	heparin	in	the	field	of	therapeutics.26,27	
1.1.3	Challenges	of	Heparin-Like	GAG	in	Analytical	Chemistry	One	 of	 the	most	 highly	 desired	 objectives	 in	 the	 field	 of	 heparin-mediated	protein	 regulation	 is	 to	understand	and	define	 the	 structure/function	 relationship	and	 finally	 decipher	 the	 sulfation	 code	 within	 the	 protein-heparin	 interactome.	However,	the	structural	diversity	exhibited	in	heparin-like	GAG	makes	this	objective	difficult	 to	 achieve	 even	 compared	 to	 the	 complex	 paradigm	 of	 protein-protein	interactions.	The	structures	of	proteins	are	usually	tightly	controlled	at	the	genetic	level,	 and	 enzymatic	modifications	 (such	 as	 phosphorylation,	which	 plays	 roles	 of	on/off	 switches	 in	 signaling)	 are	 typically	 limited	 to	 one	 (or	 a	 handful)	 per	polypeptide	chain.	Contrary	to	this,	heparin-like	GAGs	exhibit	a	dramatically	higher	level	of	structural	diversity,	and	the	segments	conferring	affinity	to	specific	targets	frequently	 are	 not	 well	 defined.	 Nevertheless,	 extensive	 efforts	 have	 been	 made	searching	 for	 specific	and	precisely	defined	GAG	sequences	capable	of	 recognizing	protein	targets	with	high	affinity.28	This	early	success	in	the	discovery	of	ArixtraTM	inspired	numerous	subsequent	searches	for	well-defined	recognition	sites	in	other	GAG-interacting	 proteins.	 Many	 of	 the	 more	 recent	 studies	 have	 led	 to	 a	 more	
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nuanced	view	of	GAG	structural	motifs	and	their	affinity	for	specific	proteins	(e.g.,	a	set	 of	 sulfate	 groups	 at	 strategic	 locations	 as	 opposed	 to	 a	well-defined	 chemical	structure29.	Besides	 the	 uncertainty	 in	 the	 mechanism	 of	 protein	 modulation,	 the	heterogeneity	 in	 samples	 of	 heparin-like	 GAG	 also	 brings	 about	 challenge	 in	analytical	strategy	itself.	Countless	modifications	make	the	simple	task	such	as	mass	measurement	 of	 protein-GAG	 complexes	 impossible.	 Measuring	 the	 mass	 would	help	 determine	 the	 binding	 stoichiometry,	 evaluate	 the	 binding	 affinity	 and	characterize	the	structure.	The	general	ideas	to	overcome	this	challenge	are	i)	to	use	a	 synthetic	 GAG	 with	 pure	 sequences	 for	 numerous	 activity	 tests	 and	 the	mechanistic	studies	or	ii)	to	seek	better	separation	strategies	or	powerful	analytical	tools,	which	are	reviewed	in	the	following	sections.	
1.2	A	Map	of	Prevailing	Arsenals	for	Studying	Heparin-Protein	Interaction	In	 this	section,	 I	enumerate	several	popular	 tools,	which	have	been	used	 in	heparin-related	studies	for	decades.	
1.2.1	Traditional	Structural	Biology	Strategies	The	mechanism	 of	 a	 modulator	 (protein	 or	 other	 ligand)	 affecting	 protein	function	is	mirrored	by	its	impact	on	protein	structure.	Traditional	tools	such	as	X-ray	 crystallography	 and	 NMR	 has	 been	 successful	 in	 answering	 this	 type	 of	questions	 by	 defining	 localization	 of	 ligand-binding	 sites	 and	 enabling	 structural	comparisons.	 High	 resolution	 structures	 are	 achieved	 by	 crystalizing	 the	 ligand-bond	protein	to	fix	a	snapshot	of	the	all-atom	coordination	and	the	electron	density	
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map	(including	the	intensity	and	phasing)	generated	based	on	the	X-ray	diffraction	data	is	used	to	build	up	the	structural	model.	This	approach	has	been	performed	in	order	 to	 completely	 understand	 how	 heparin-like	 GAG	 regulates	 the	 function	 of	proteins.	 And	 in	 all	 of	 these	 cases,	 a	 synthetic	 oligosaccharide	 was	 utilized.	 The	heparin-binding	 site	 of	 AT	 and	 the	 allosteric	 activation	model	 in	 the	 inhibition	 of	Factor	 Xa	 was	 also	 acquired	 using	 this	 approach,8,30	 where	 a	 fully	 sulfated,	 pure	pentasaccharide	 was	 used.	 From	 the	 crystal	 structures	 we	 clearly	 see	 that	 AT	activation	 upon	pentasaccharide	 binding	 is	 the	 crucial	 step	 for	 Xa	 inhibition.	 This	mechanism	agrees	with	 the	earlier	discovery	 that	 the	 ternary	complex	of	heparin-AT-Xa	does	not	require	a	direct	interaction	between	heparin	and	the	protease	Xa16,	while	the	ternary	complex	formed	by	AT-heparin-thrombin	does.	The	structures	of	the	ternary	complex	were	solved	by	two	groups	in	the	same	year31,32;	they	both	used	mimetic	 heparin	 polysaccharide	 containing	 two	 negative	 charged	 domains,	 which	enabled	 them	 to	 bind	 AT	 and	 thrombin	 individually.	 As	 another	 giant	 family	 of	heparin-binding	 proteins,	 the	 fibroblast	 growth	 factors	 (FGF)	 initiate	 signaling	related	to	cell	proliferation	and	differentiation	through	the	binding	to	the	fibroblast	growth	factor	receptor	(FGFR),	which	can	be	facilitated	by	the	mediation	of	heparan	sulfate.	 A	 series	 of	 FGF•FGFR	 structures	 in	 the	 presence	 or	 absence	 of	 heparin	oligomer	were	resolved	for	different	protein	subspecies33-35.	Some	dynamic	regions	(e.g.	 the	 GAG	 units	 unbound	 or	 nonspecifically	 bound	 to	 the	 protein)	 were	 likely	missing	 from	 the	 electron	 density	 map.	 Nevertheless,	 crystallography	 is	 still	 the	most	reliable	approach	to	understanding	the	role	of	certain	modification	pattern	in	protein	 binding	 (by	 tracking	 the	 hydrogen	 bonds	 and	 salt	 bridges).	 Compared	 to	
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crystallography,	 NMR	 can	 generate	 structural	 models	 embracing	 more	kinetic/dynamic	 information.	 In	solution,	protein	structure	 in	the	presence	of	GAG	can	 also	 be	 resolved	 using	 NMR,	 which	 provides	 some	 critical	 insights	 regarding	heparin-mediated	 FGF-FGFR	 interaction	 and	 thrombosis.36-38	 It	 should	 be	 noted,	that	 structural	 modeling	 can	 be	 interpreted	 in	 an	 unbiased	 fashion	 only	 if	 the	relationship	between	protein	function	and	the	structural	variety	of	heparin-like	GAG	has	 been	 elucidated	 through	 other	 empirical	 and	 experimental	 approaches.	 It	 is	critical	 to	choose	an	appropriate	binding	element	to	generate	a	snapshot	that	may	also	represent	the	scenarios	for	other	related	binders.	
1.2.2	Physical	Chemistry	Strategies	The	 hypothesis	 that	 the	 functional	 effects	 of	 heparin	 arise	 from	 specific	interaction	between	positive	residues	of	proteins	and	sulfate	groups	of	heparin-like	GAGs	 can	 be	 demonstrated	 using	model	 saccharides	 and	 solving	 the	 structure.	 If	true,	 the	 redundant	 sulfate-containing	 disaccharide	 may	 not	 participate	 in	 the	protein	regulation	based	in	the	“key-to-lock”	model.	Physical	chemistry	fills	the	gap	caused	 by	 a	 universal	 electrostatic	 interaction	 with	 the	 polyanion-particle	interaction	model	 emphasizing	 the	 roles	 of	 charge	 density	 in	 binding	 affinity	 and	many	 heparin-mediated	 effects,	 such	 as	 protein	 aggregation39,40.	 This	 approach	provides	better	insights	regarding	the	universal	basis	of	heparin/protein	interaction	in	 solution.	 Many	 tools	 for	 biophysical	 chemistry	 studies	 have	 also	 been	 used	including	 capillary	 electrophoresis	 (for	measurement	 of	mobility),	 light	 scattering	techniques	 (for	 measurement	 of	 size	 distribution)	 and	 isothermal	 calorimetric	
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titration	 (for	 measurement	 of	 binding	 affinity).	 These	 techniques	 are	 usually	tolerant	 to	 the	 structural	variety	 to	 some	extent	and	can	deal	with	heterogeneous	sample	 directly	 without	 extra	 separation.	 One	 fruit	 we	 have	 harvested	 from	 this	area	 is	 the	 knowledge	 that	 binding	 affinity	 (perhaps	 contributed	 by	 non-specific	electrostatic	interaction)	is	affected	by	environmental	factors	including	pH	and	ionic	strength,	which	 is	 valuable	 information	 for	 us	 in	 choosing	 a	 condition	 in	 order	 to	strengthen	the	global	binding	affinity	and/or	minimize	non-specific	binding.	
1.2.3	Mass	Spectrometry-Based	Strategies	Mass	 spectrometry	 holds	 several	 advantages	 when	 being	 applied	 to	 the	heparin-related	 analysis:	 i)	 moieties	 rich	 in	 sulfate	 provide	 numerous	 negative	charges	(in	the	electrospray	source)	and	enhances	the	detection	of	the	ions	(in	the	negative	ion	mode);	ii)	all	successfully	ionized	heparin	molecules	can	be	displayed	simultaneously	 in	a	mass	spectrum	and	those	peaks	representing	different	masses	can	be	distinguished	as	long	as	the	resolving	power	and	dynamic	range	of	the	mass	analyzer	 can	 tolerate	and	accurately	 reflect	 the	heterogeneity	 in	 the	 sample.	Mass	spectrometry	 is	 a	 perfect	 analytical	 tool	 for	 many	 applications	 including	 GAG	sequence	 mapping,	 protein	 epitope	 mapping	 and	 GAG-bound	 protein	 structure	characterization.	
1.2.3.1	Mass	Spectrometry-Based	“Proteomics”	The	 robustness	 of	 mass	 spectrometry	 is	 tightly	 associated	 with	 the	 most	straightforward	tasks:	to	characterize	the	identity	of	GAG	molecules	in	terms	of	the	mass,	 structure	 and	 sometimes	 the	 abundance	 in	 the	 background	 of	 many	 other	
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species.	 The	 applications	 for	 this	 technology	may	 range	 from	 completely	 profiling	heparin-like	GAG	in	naturally-occurring	samples	to	identifying	the	heparin	segment	interacting	 with	 partner	 proteins.	 The	 area	 of	 glycosaminoglycanomics	 aiming	 at	analyzing	the	GAG	sample	extracted	from	different	tissues,	cell	types	and	individuals	borrows	the	following	means	from	regime	of	proteomics.	(1)	 Similar	 to	 the	 “bottom-up”	 strategy	 in	 proteomics,	 unfractionated	heparin-like	 GAGs	 need	 to	 be	 digested	 to	 small	 segments	 in	 order	 to	 be	 analyzed	effectively41.	The	segments	can	be	further	restrained	if	the	purpose	is	to	screen	the	segments	that	can	tightly	bind	to	a	protein.	The	digested	mixture	as	a	library	often	passes	through	a	protein-immobilized	column.	(2)	The	high-throughput	 analysis	 relies	on	a	LC	 separation	prior	 to	 the	MS	analysis.	Similar	to	the	platform	of	proteomics,	the	LC	separation	can	be	combined	with	MS	in	an	online	fashion42.	The	types	of	separation	for	GAG	can	be	RPC,	HILIC	and	SEC.		(3)	Deconvolution	of	the	spectra	is	based	on	database	search	for	a	structural	assignment	at	MS	 level.	Recently,	 the	Zaia	group	utilized	an	optimized	online	SEC-MS	approach	to	analyze	a	GAG	sample	and	successfully	 identified	species	with	 the	chain	length	up	to	30	saccharide	units.43	(4)	Identification	of	GAG	segments	can	be	done	at	the	MS/MS	level	to	fulfill	advanced	 ion	 monitoring	 and	 structural	 analysis.	 For	 example,	 Linhardt	 and	 his	collaborators	 in	 China	 developed	 a	 LC-MRM	 method	 to	 quantitatively	 analyze	disaccharide	 from	 cell	 culture.	 Like	 proteomics	 employing	 MS/MS	 for	 peptide	sequencing,	 cross-ring	 fragmentation	 of	 GAG	 can	 allow	 us	 to	 localize	 the	
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modifications.	The	Amster	group	 introduced	electron-detached	dissociation	 (EDD)	technique	 into	 this	 field,	 which	 can	 generate	 a	 huge	 number	 of	 fragment	 ions	consisting	in	the	cross-ring	fragmentations	and	does	not	induce	sulfate	shedding.44	However,	EDD	has	to	be	carried	using	an	incredibly	long	acquisition	time	and	hence	it	 is	 impossible	 to	 run	 with	 online	 LC	 separation.	 The	 Sharp	 group	 recently	developed	a	CID-based	online	LC-MS/MS	platform	where	 the	 labile	 sulfate	 groups	for	 CID	 are	 derived	 to	 isotopic-labeled	 acetylated	 group	 during	 the	 sample	preparation	step45.		
1.2.3.2	Native	Mass	Spectrometry	for	Protein-GAG	Complex	In	 native	 mass	 spectrometry,	 the	 solution	 conformation	 and	 non-covalent	structure	 of	 protein	 complexes	 can	 be	 maintained	 to	 a	 large	 extent.	 One	 of	 the	merits	 of	 using	 native	 mass	 spectrometry	 for	 characterization	 of	 protein-GAG	complex	in	the	gas-phase	is	that	the	electrostatic	interactions	between	protein	and	GAG	 are	 strengthened	 and	 hence	 the	 complexes	 can	withstand	 harsh	 desolvation	conditions.	An	intrinsic	drawback	of	native	mass	spectrometry	is	the	modest	mass	accuracy	 in	 the	 high	m/z	 regions,	 so	 it	 usually	 hinders	 native	mass	 spectrometry	being	primarily	chosen	for	identification	of	the	ions	with	significant	mass	variation.	However	 modern	 mass	 spectrometer	 (e.g.	 FT-ICR)	 dramatically	 improves	 the	resolving	power	and	mass	accuracy	for	a	wide	range	of	heterogeneous	analytes.	For	example,	 AT	was	 incubated	with	 a	 combinatorial	 hexasaccharide	 library	 and	was	analyzed	 in	 a	manner	 of	 intact	 complexes	 under	 the	 native	 condition.	As	 a	 result,	peaks	 represent	 AT	 interacting	 with	 different	 dp6	 members	 displayed	 in	 the	
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spectrum	and	have	adequate	resolution	to	determine	the	number	of	sulfate	groups	and	 ammonium	 adduct.	 A	 semi-quantitation	 was	 achieved	 based	 on	 the	 peak	areas46.	Another	 potential	 value	 of	 native	 mass	 spectrometry	 is	 that	 the	 ions	 with	near-native	 structure	 can	 be	 further	manipulated	 in	 the	 gas	 phase,	which	 reflects	meaningful	 information	 regarding	 the	 structure	 and	 stability.	 In	 another	 work	related	to	AT	interacting	with	pentasaccharides,	the	collisional	cross	section	(i.e.	the	average	projection	area	of	a	 tumbling	 ion)	of	native	 ion	of	complex	was	estimated	using	 ion-mobility	 spectrometry	 as	 a	 supplemental	 measurement	 of	 native	 mass	spectrometry.47	
1.3	Future	Directions:	State-of-Art	Mass	Spectrometry-Based	Techniques	Although	current	 tools	described	 in	previous	sections	hold	 the	keys	 to	vast	array	 of	 heparin-related	 questions,	 the	 limiations	 of	 those	 techniques	 present	analytical	 challenges	 caused	 by	 heterogeneous	 structure	 and	 diverse	 function	 of	heparin-like	 GAG.	 To	 push	 the	 boundaries	 toward	 the	 better	 elucidation	 of	structure/diversity	relationship,	 I	will	explore	some	emerging	mass	spectrometry-based	techniques	in	this	dissertation.	The	mainly	relevant	techniques	are	discussed	as	 following,	 which	 aim	 at	 increasing	 a	 dimension	 of	 separation	 an	 may	 be	promising	to	solve	heterogeneity-related	problems.	
1.3.1	Ion-Mobility	Spectrometry	Mass	Spectrometry	In	traveling	wave	ion-mobility	spectrometry,	the	gas-phase	mobility	of	an	ion	is	measured	based	on	its	arrival	time	when	passing	through	a	plate-stacking	cell	in	
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the	buffering	gas.	Mobility	of	an	ion	can	be	converted	to	CCS,	which	is	a	reflection	of	the	 particle	 size	 and	 structural	 features.	 It	 is	 still	 controversial	 whether	 the	structural	model	predicted	based	on	measured	CCS	values	and	MD	simulations	can	be	 trusted.	 Nevertheless,	 ion-mobility	 spectrometry	 is	 absolutely	 a	 powerful	separation	 tool	 even	 for	 the	 molecules	 with	 small	 structural	 differences.	Interestingly,	 ion-mobility	measurements	are	enabled	 for	both	precursor	 ions	and	product	ions,	in	a	MS/MS	experiment.	Li’s	group	has	reported	work	involving	IMS	to	locate	a	single	epimeric	amino	acid	within	a	peptide	by	comparing	arrival	times	for	fragment	ions48.		For	heparin	and	heparin-protein	complexes,	structural	variety	may	lead	to	a	MS	 peak	 convolution.	 The	 ion-mobility	 separation	 will	 potentially	 increase	 the	resolution	 by	 increasing	 an	 extra	 dimension	 of	 separation.	 This	 feature	 will	 be	demonstrated	and	reiterated	in	following	chapters	(Chapter	2	through	4).	
1.3.2	Novel	Online	LC-Native	MS	for	Protein	complexes	Native	MS	can	be	 combined	with	 size	exclusion	chromatography	 (SEC)	and	ion	 exchange	 chromatography	 (IXC)	 in	 an	 online	 fashion.	 Our	 group	 is	 one	 of	 the	pioneers	 to	 explore	 the	 feasibility	 of	 SEC-MS49	 and	 IXC-MS50	 and	 its	 potential	applications.	 This	 technique	 has	 now	 drawn	 quite	 a	 lot	 of	 attention	 from	 many	groups	in	industry.	It	can	be	used	to	characterize	highly	heterogeneous	sample	such	as	those	proteins	containing	combinations	of	post-translational	modifications.	It	 has	 been	 reviewed	 previously	 that	 SEC-MS	 is	 a	 perfect	 tool	 for	 high-throughput	 profiling	 low-molecular-weight	 heparin,	 because	 the	 species	 with	
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different	 chain	 length	 are	 retained	 on	 the	 column	 for	 different	 time	 and	 can	 be	identified	 individually.	 This	 feature	 should	 work	 for	 protein-heparin	 complex	 as	well	under	the	native	condition	in	order	to	reduce	the	peak	convolution.	Online	SEC-native	MS	will	be	an	important	tool	for	achieving	our	goal	in	the	fourth	chapter.		
1.3.3	Gas-phase	chemistry	for	manipulation	of	gaseous	ions	The	 last	 approach	 to	 enhance	 the	 analytical	 dimensions	 is	 the	 use	 of	quadrupole.	 In	 another	 words,	 gas-phase	 chemistry	 including	 collision-induced	activation	and	electron-transfer-induced	limited	charge	reduction	can	be	applied	on	a	 mass-selected	 population.	 And	 the	 latter	 has	 been	 verified	 to	 be	 promising	 in	determining	 the	 mass	 for	 heterogeneous	 protein	 systems.51	 The	 most	 intriguing	aspect	 of	 this	 is	 that	 the	 gas-phase	 chemistry	 can	 be	 combined	 with	 other	 two	separation-tools	mentioned	 above	 and	 give	 rise	 to	 a	 three-dimensional	 analytical	platform.	 The	 combination	 of	 charge-reduced	 or	 activated	 ions	 and	 ion-mobility	separation	will	be	reiterated	in	Chapter	2,3,4.		 	
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Figure	1-1.	The	wide	size	range	(1-50	kDa)	and	enormous	diversity	of	
sulfation	patterns	epitomize	the	extreme	structural	heterogeneity	of	heparin	
and	related	GAGs		 	
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Figure	1-2.	Schematic	representation	of	a	nanogel	construct	utilizing	heparin-
based	linkers	to	load	growth	factors	and	morphogens	(labeled	as	HBPs,	
heparinbinding	proteins)	for	delivery	to	tissues		 	
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CHAPTER	2	
	
INTERACTIONS	OF	INTACT	UNFRACTIONATED	HEPARIN	WITH	ITS	CLIENT	
PROTEINS	CAN	BE	PROBED	DIRECTLY	USING	NATIVE	ELECTROSPRAY	
IONIZATION	MASS	SPECTROMETRY*	
2.1	Introduction	Glycosaminoglycans	(GAGs)	are	ubiquitous	linear	polysaccharides	that	carry	out	 diverse	 functions	 in	 the	 human	body,1	with	 heparin	 being	perhaps	 one	 of	 the	best	 known	 GAGs	 due	 to	 its	 widespread	 use	 in	medicine	 as	 an	 anticoagulant.2	 In	addition	 to	 its	 critical	 involvement	 in	 the	 blood	 coagulation	 cascade,	 heparin	 (as	well	as	its	next-of-kin	heparan	sulfate3)	possesses	a	broad	range	of	other	clinically	relevant	 properties.4,5	 Despite	 the	 widely	 acknowledged	 therapeutic	 potential	 of	heparin	 and	 heparin-like	 GAGs	 in	 clinical	 fields	 ranging	 from	 oncology	 to	neurodegenerative	 diseases	 to	 tissue	 engineering,6-10	 their	 use	 remains	disappointingly	limited	outside	of	the	anticoagulant	field.11	One	of	the	major	reasons	for	 that	 is	 the	 extreme	 structural	 heterogeneity	 of	 heparin,	 which	 makes	 it	 very	difficult	to	decipher	the	molecular	mechanisms	of	its	interaction	with	nearly	half-a-thousand	 proteins	 comprising	 GAG	 interactome.12	 Even	 the	 mundane	 task	 of	determining	 the	 composition	 and	 binding	 stoichiometry	 of	 heparin/protein	complexes	remains	presently	unattainable	(unless	intact	heparin	is	substituted	with	relatively	 homogeneous	 short	 fragments13-16	 or	 synthetic	 mimetics17).	 Sequence	polydispersity	of	heparin	and	related	GAGs	arises	from	their	biosynthesis,	in	which																																																									*	This	chapter	is	an	authorized	reprint	of	the	article	published	by	Zhao,	et	al.	in	
Analytical	Chemistry	88	1711-1718	(2016).	
	 22	
enzymatically-controlled	modifications	of	precursor	 linear	polysaccharides	 lead	 to	truly	 intimidating	 variability	 in	 the	 levels	 and	 patterns	 of	O-	 and	N-sulfation	 and	deacetylation.	These	countless	modification	patterns	(which	appear	to	be	stochastic,	but	are	 in	 fact	exquisitely	regulated	and	biofunctional),	as	well	as	the	chain	 length	variation,	 present	 a	 truly	 Herculean	 task	 vis-a-vis	 analytical	 characterization	 of	heparin	and	its	interaction	with	client	proteins.	Among	the	many	experimental	techniques	used	in	biophysics	and	structural	biology	 to	 probe	 biopolymer	 interactions,	 native	 electrospray	 ionization	 mass	spectrometry	 (ESI	MS)18-20	 stands	out	as	a	versatile	 tool	 that	 is	not	 limited	by	 the	physical	 size	 of	 the	 non-covalent	 assemblies	 and	 is	 capable	 of	 observing	multiple	species	 in	 solution	 as	 long	 as	 the	 distinction	 can	 be	 made	 on	 the	 basis	 of	 mass.	However,	in	a	case	of	highly	heterogeneous	samples	native	ESI	MS	(as	well	as	ESI	MS	measurements	carried	out	under	denaturing	conditions)	fail	to	provide	meaningful	information	due	to	extensive	overlap	of	 ionic	peaks	corresponding	to	species	with	different	masses	but	similar	or	indeed	identical	m/z	values;	in	extreme	cases	these	overlaps	 may	 give	 rise	 to	 a	 continuum	 distribution	 of	 ionic	 signal	 without	 any	discernable	 features.21	 Historically,	 complexity	 reduction	 of	 ESI	 mass	 spectra	 of	heterogeneous	 samples	 was	 achieved	 by	 introducing	 a	 separation	(chromatographic)	 step	 into	 the	 workflow,22	 which	 requires	 the	 use	 of	 non-denaturing	chromatography	(such	as	size	exclusion),	 if	the	separation	step	is	to	be	combined	with	native	ESI	MS.23	Instead	of	(or	sometimes	in	addition	to)	introducing	a	solution-phase	separation	step,	ion	mobility	can	provide	an	orthogonal	separation	dimension	 in	 the	 gas	 phase	 to	 aid	 MS	 analysis	 of	 complex	 samples.24,25	
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Interpretation	 of	 highly	 congested	mass	 spectra	 can	 also	 be	 aided	 by	 using	 ultra-high	resolution	mass	analyzers	capable	of	resolving	even	very	closely	spaced	ionic	peaks,26	although	this	approach	is	typically	used	for	relatively	low-molecular	weight	analytes,	while	its	applications	in	the	analysis	of	heterogeneous	biopolymers	remain	limited.	Finally,	spectral	congestion	can	be	frequently	brought	to	an	acceptable	level	by	reducing	the	charge	states	of	biopolymer	ions	via	e.g.	proton	transfer	reactions	in	the	gas	phase.27		Recently,	 we	 introduced	 an	 approach	 that	 combines	 complexity	 reduction	(mass-selection	 of	 a	 narrow	 distribution	 of	 ionic	 species	 from	 a	 heterogeneous	mixture)	 and	 either	 electron	 transfer	 to	 or	 electron	 capture	 by	 the	 selected	 ions	without	 subsequent	 dissociation	 to	 induce	 partial	 reduction	 of	 the	 ionic	 charge.28	The	resulting	spectra	are	easy	to	 interpret,	 leading	to	correct	mass	assignment	for	biopolymer	 assemblies	 as	 large	 as	 0.5	 MDa.29	 Using	 the	 electron-based	 charge	reduction	schemes	as	opposed	to	proton-transfer	reactions	allows	this	approach	to	be	applied	 to	macromolecular	 ions	 in	which	 the	majority	of	cationizing	agents	are	not	 protons	 (e.g.,	 synthetic	 polymers	 and	nanoparticles).	 Since	 the	 gas-phase	GAG	polycation	 formation	 usually	 proceeds	 via	 alkali	 metal30,31	 or	 ammonium	 adduct	formation,15	electron-based	charge	reduction	should	also	be	well-suited	for	heparin	and	its	complexes	with	the	client	proteins.	In	the	present	work	we	use	this	approach	to	 obtain	 meaningful	 information	 on	 complexes	 formed	 by	 intact	 unfractionated	heparin	 with	 a	 paradigmatic	 heparin-binding	 protein,	 antithrombin-III	 (AT).	Complexes	of	multiple	stoichiometries	(up	to	three	AT	molecules	per	single	heparin	chain)	are	detected	alongside	free	(unbound	heparin).	We	also	demonstrate	that	a	
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combination	of	this	technique	with	ion	mobility	separation	in	the	gas	phase	allows	the	 total	 analysis	 time	 to	 be	 decreased	 dramatically.	 The	 ability	 to	 detect	 distinct	heparin/protein	complexes	demonstrated	in	this	work	expands	the	reach	of	native	ESI	MS	 into	 the	 field	where	 analytical	 options	 have	been	 very	 limited	 so	 far.	 This	development	will	undoubtedly	have	a	significant	 impact	not	only	by	catalyzing	the	studies	 of	 the	 mechanisms	 governing	 the	 interactions	 of	 heparin-like	 GAGs	 with	their	 client	 proteins,	 but	 also	 by	 assisting	 the	 design	 of	 new	 and	 effective	 drug	delivery	 systems	utilizing	heparin	 as	 a	 scaffold	 in	 areas	 ranging	 from	oncology	 to	tissue	regeneration.32-34	
2.2	Experimental	
2.2.1	Materials	Porcine	 heparin	 (from	 mast	 cells)	 was	 purchased	 from	 Sigma-Aldrich	Chemical	Company	(St.	Louis,	MO)	and	used	without	any	purification,	fractionation	or	enzymatic	treatment.	High	heparin-affinity	fraction	of	antithrombin-III	(AT)	was	a	 generous	 gift	 from	 Professor	 Paul	 Dubin	 (UMass-Amherst).	 All	 solvents,	 buffers	and	 salts	 were	 of	 analytical	 grade	 or	 higher.	 The	 stock	 heparin	 solution	 was	prepared	 by	 directly	 dissolving	 weighed	 powder	 in	 water	 and	 the	 stock	 protein	solution	 was	 cleaned	 via	 buffer	 exchanging	 into	 30	 mM	 solution	 of	 ammonium	acetate	 using	 ultrafiltration.	 The	 heparin/AT	 mixture	 was	 prepared	 immediately	before	the	MS	analysis	without	extended	incubation.	The	final	concentrations	of	AT	and	heparin	were	0.025	mg/mL	and	0.03	mg/mL,	respectively.	
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2.2.2	Methods	All	MS	and	ion	mobility	measurements	were	carried	out	with	a	Synapt	G2-Si	HDMS	(Waters	Corp.,	Milford,	MA)	mass	spectrometer	equipped	with	a	nanospray	ionization	 source.	 To	 minimize	 collisional	 activation	 of	 ions	 transferrin	 the	 ESI	interface	 region,	 the	 following	 parameters	were	 kept	 at	minimal	 values:	 sampling	cone	 voltage,	 trap	 CE,	 trap	DC	 bias	 and	 transfer	 CE.	 Ion	 selection	 prior	 to	 limited	charge	 reduction	 in	 the	 trap	was	 carried	out	by	 setting	quadruple	parameters	 for	different	width	of	ion	transmission	window:	LM	resolution,	2	–	4;	HM	resolution,	15;	and	offset	voltage,	0.	To	trigger	electron	transfer	reactions,	the	trap	wave	height	was	set	 at	 0.5	 V.	 ETD	 recharging	 current	 was	 also	 optimized	 (typically	 8	 –	 20	 A)	 for	sufficient	intensity	of	charge-reduced	species.	Post-acquisition	processing	of	MS	and	IMS	 data	 was	 carried	 out	 using	 MassLynx	 4.1	 and	 DriftScope	 2.6,	 respectively	(Waters	 Corp.,	Milford,	MA).	 Curve	 fitting	was	 done	 using	OriginPro	 (Origin	 Labs,	Northampton,	MA).	
2.3	Results	and	Discussion	
2.3.1	Characterization	of	protein/heparin	complexes	using	“traditional”	native	
ESI	MS	and/or	ion	mobility	spectroscopy	Native	ESI	MS	provides	an	elegant	way	to	monitor	interactions	of	short	and	relatively	homogeneous	heparinoids	with	proteins;13-17	however,	application	of	this	technique	to	 larger	systems	(such	as	 intact	heparin)	 is	not	straightforward.	Figure	2-1	 shows	native	ESI	mass	 spectra	of	AT	 in	heparin-free	 solution	and	AT/heparin	mixture.	 The	 mass	 spectrum	 of	 heparin-free	 AT	 contains	 contributions	 from	 two	glycoforms,	which	are	commonly	referred	to	as	α-	and	β-AT	(molecular	weights	57.9	
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and	55.7	kDa,	respectively),35,36	with	the	latter	accounting	for	over	90%	of	the	total	ionic	signal.	The	mass	spectrum	of	the	AT/heparin	mixture	displays	abundant	ionic	signal,	while	at	the	same	time	showing	that	the	signal	of	free	(unbound)	AT	is	nearly	eliminated,	 suggesting	 that	 strong	 binding	 takes	 place	 between	 the	 protein	molecules	 and	 the	 GAG	 chains.	 However,	 the	 ionic	 signal	 above	m/z	 4,000	 is	 a	completely	 unresolved	 continuum	 distribution	 that	 spans	 several	 thousand	 m/z	units.	 Even	 though	 the	 distribution	 is	 not	 monotonic,	 and	 some	 features	 can	 be	discerned,	it	is	impossible	to	obtain	any	meaningful	information	related	to	the	ionic	masses.	 Likewise,	 IMS	analysis	 of	 the	AT/heparin	mixture	 reveals	 the	presence	of	several	semi-distinct	(partially	overlapping)	ionic	populations	(see	Figure	2-S1	in),	but	 the	 additional	 separation	 afforded	 by	 the	 mobility	 measurements	 in	 the	 gas	phase	clearly	is	not	sufficient	for	obtaining	interpretable	IM-MS	patters	from	which	the	masses	of	putative	AT/heparin	complexes	could	be	deduced.		
2.3.2	Limited	charge	reduction	of	heparin	polycations	in	the	gas	phase	is	
accompanied	only	by	minimal	ion	dissociation	We	approached	the	task	of	measuring	the	masses	of	AT/heparin	complexes	initially	by	isolating	relatively	narrow	ionic	populations	in	the	gas	phase	followed	by	their	charge	reduction	using	electron	transfer	reactions,	a	technique	initially	tested	on	 extensively	 glycosylated	 proteins,28	 and	 later	 applied	 to	 large	 protein	complexes29	and	aggregates.37	Electron-driven	charge	reduction	of	the	polycationic	species	 in	 the	 gas	 phase	 is	 ideally	 suited	 for	 heparin,	 as	 ESI-generated	 heparin	polycations	 are	 largely	 alkali	 metal-	 and	 ammonium	 adducts,	 rather	 than	protonated	species,	which	is	likely	to	make	the	use	of	proton	transfer	reactions	for	
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the	charge	reduction	purposes	 ineffective.	However,	electron	transfer	 to	a	heparin	(or	heparin-containing)	polycation	generates	 a	 free	 radical,	which	may	 induce	 ion	fragmentation	 in	 the	 gas	 phase.	 If	 the	 charge	 reduction	 is	 not	 accompanied	 by	collisional	 activation	 of	 ions,	 such	 fragmentation	 events	 are	 unlikely	 to	 lead	 to	dissociation	(physical	separation)	of	the	fragments	in	the	gas	phase	when	applied	to	globular	proteins	and	protein	complexes,	where	multiple	hydrogen	bonds	reinforce	ternary	and	quaternary	structures.38	In	fact,	ion	dissociation	was	never	observed	in	our	previous	work	when	electron-based	(both	transfer	and	capture)	limited	charge	reduction	was	applied	to	proteins,	their	complexes	and	aggregates	under	conditions	that	 minimize	 collisional	 activation.28,29,37	 However,	 GAG	 chains	 are	 linear	 and	unlikely	 to	 collapse	 to	 globular	 structures	 upon	 transfer	 from	 solution	 to	 the	 gas	phase	 in	 the	 ESI	 interface.	 Therefore,	 generating	 a	 free	 radical	 in	 the	 process	 of	electron-driven	 charge	 reduction	 may	 conceivably	 result	 in	 dissociation	(fragmentation	 followed	 by	 physical	 separation	 of	 the	 fragments),	 unless	 the	affected	 chemical	 bond	 is	 part	 of	 the	 saccharide	 ring	 (in	 which	 case	 a	 cross-ring	cleavage	would	be	required	for	dissociation).		To	 evaluate	 the	 likelihood	 of	 such	 unintended	 dissociation	 of	 heparin	 and	heparin-containing	 polycations	 in	 the	 gas	 phase	 when	 collisional	 activation	 is	minimized,	 we	 applied	 the	 limited	 charge	 reduction	 technique	 to	 the	 ions	representing	 free	 (unbound)	 heparin	 in	 the	 mass	 spectrum	 of	 the	 AT/heparin	mixture.	Figure	2-2	shows	the	results	of	limited	charge	reduction	of	ions	confined	to	a	narrow	ionic	population	(m/z	3190-3230)	that	was	selected	from	the	region	of	the	AT/heparin	mass	spectrum	populated	by	free	heparin	ions.	The	vast	majority	of	
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product	ions	appear	in	the	m/z	region	above	that	of	the	precursor	ions;	only	a	small	fraction	of	ions		representing	less	than	1%	of	the	total	ionic	signal	appear	below	the	low-mass	cutoff	 for	 the	precursor	 ion	selection	window	(see	 the	colored	region	 in	the	inset	in	Figure	2-2)	and,	therefore,	are	fragment	ions.	In	addition	to	these	low-
m/z	 fragments,	 some	 of	 the	 product	 ions	 populating	 the	 region	 of	 the	 spectrum	above	 the	 mass	 selection	 window	 can	 also	 be	 fragment	 ions	 (with	 low	 charge	states).	 However,	 analysis	 of	 their	m/z	 values	 suggests	 that	 the	 vast	 majority	 of	them	 are	 simply	 products	 of	 ionic	 charge	 reduction,	 and	 if	 any	 dissociation	 does	accompany	this	process,	it	results	only	in	a	very	small	mass	change.		This	analysis	was	carried	out	by	assigning	a	random	integer	charge	state	Z	to	the	 precursor	 ion	 population	 within	 the	 selection	 window	 and	 calculating	 the	masses	of	charge-reduced	species	Z-1,	Z-2,	etc.	The	results	of	these	calculations	are	shown	 in	Figure	 2-2	with	 colored	 arrows,	 each	 color	 corresponding	 to	 a	 specific	mass	and	charge	state	of	the	precursor	ions	(as	indicated	in	Figure	2-2).	Changing	the	position	of	the	precursor	ion	selection	window	will,	of	course,	allow	a	different	set	of	 free	heparin	molecules	 to	be	detected,	and	complete	“cataloging”	of	 the	 free	heparin	 species	 would	 require	 the	 precursor	 ion	 selection	 window	 to	 be	 moved	across	the	entire	m/z	region	of	interest	(a	point	that	will	be	addressed	later).	In	the	mass	 spectrum	 of	 the	 products	 of	 limited	 charge	 reduction	 shown	 in	Figure	 2-2	there	are	four	different	groups	of	heparin	polycations	with	m/z	ratios	falling	within	the	precursor	ion	selection	window,	ranging	from	16	to	26	kDa.	The	mass	spectrum	does	not	contain	any	“orphan”	ions	in	the	m/z	region	above	that	of	the	precursor	ion	selection	window	that	cannot	be	assigned	as	products	of	charge	reduction	without	
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dissociation.	Similar	conclusions	can	be	drawn	from	the	analysis	of	charge-reduced	heparin	 ions	 whose	 precursors	 were	 selected	 from	 different	 m/z	 windows	suggesting	that	no	significant	dissociation	of	heparin	polycations	occurs	as	a	result	of	 electron-driven	 limited	 charge	 reduction	 under	 conditions	 that	 minimize	collisional	 activation.	 Even	 lower	 dissociation	 yields	 are	 expected	 for	 heparin-protein	assemblies,	where	strong	electrostatic	interactions	are	expected	to	provide	additional	structural	reinforcement	in	the	gas	phase.	
2.3.3	Establishing	the	identity	of	AT/heparin	complexes	using	limited	charge	
reduction	Even	 though	 straightforward	 use	 of	 native	 ESI	 MS	 or	 IM-MS	 of	 the	AT/heparin	mixture	does	not	allow	meaningful	information	to	be	extracted	from	the	unresolved	mass	 spectra,	 some	spectral	 features	 could	nonetheless	be	 seen	 in	 the	high	m/z	region	that	hint	at	the	presence	of	protein/GAG	complexes	with	different	stoichiometries,	 each	 giving	 rise	 to	 a	 continuum	 ionic	 signal.	 For	 example,	 ions	 in	the	m/z	region	4500-5500	(immediately	above	that	of	AT	ions)	may	represent	1:1	AT/heparin	complexes,	while	the	ability	of	a	single	heparin	chain	to	accommodate	more	 than	 one	 protein	may	 give	 rise	 to	 ions	with	 higher	m/z	 values.	 In	 order	 to	confirm	 that	 and	 identify	 the	 regions	 corresponding	 to	 different	 protein	 loading,	precursor	ions	were	selected	within	broad	(100	m/z	units)	windows	and	subjected	to	limited	charge	reduction.	Three	representative	mass	spectra	of	ions	produced	by	limited	charge	reduction	of	precursor	ions	representing	the	three	distinct	regions	in	the	native	ESI	mass	spectrum	of	the	AT/heparin	mixture	are	shown	in	Figure	2-3.	The	m/z	values	of	 ion	peaks	 from	the	well-defined	charge	 ladder	representing	 the	
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precursor	ions	at	highest	m/z	(selection	window	6850-7050)	can	be	readily	used	to	obtain	 the	masses	 of	 ions	 populating	 this	 region	 of	 the	mass	 spectrum	 (189,	 196,	203,	 210	 kDa,	 corresponding	 to	AT3·heparin	 complex).	 The	 analysis	 of	 the	 charge	ladder	 representing	 the	 precursor	 ions	 at	 lowest	m/z	 values	 (4750-4850)	 is	 also	relatively	straightforward,	yielding	four	ionic	species	in	the	62−77	kDa	mass	range	(corresponding,	 as	 expected,	 to	 AT·heparin	 complex,	 vide	 supra;	 see	 the	 panel	
labeled	 “m/z	=	4800”	 in	 the	 Supporting	 Information	 for	more	detail).	 However,	 the	mass	spectrum	of	the	products	of	charge	reduction	of	precursor	ions	confined	to	the	isolation	window	m/z	 5950-6050	 (purple	 trace	 in	Figure	 2-3)	 is	 very	 convoluted	and	cannot	be	interpreted	unequivocally	without	making	any	assumptions.		This	overwhelming	spectral	complexity	is	likely	to	be	due	to	the	presence	of	multiple	 AT/heparin	 complexes	 whose	 m/z	 values	 fall	 within	 a	 relatively	 wide	precursor	ion	selection	window.	In	order	to	circumvent	this	problem	and	to	simplify	the	data	analysis	process,	another	mass	spectrum	was	collected	after	narrowing	the	width	 of	 the	 precursor	 ion	 selection	 window	 ten-fold	 (m/z	 5995-6005).	 The	resulting	mass	spectrum	(the	cyan	trace	in	Figure	2-4)	is	indeed	greatly	simplified	compared	 to	 the	 original	 spectrum	 and	 contains	 contributions	 from	 only	 three	distinct	 ionic	 species	 corresponding	 to	 AT2·heparin	 complexes	 with	 different	heparin	chain	lengths	(14.6,	20.6	and	26.6	kDa,	respectively),	while	the	majority	of	other	charge-reduced	species	that	were	prominent	in	the	original	spectrum	(purple	trace	 in	Figure	 2-4)	 are	 filtered	 out.	 For	 example,	 a	 peak	 at	m/z	 6435	 is	 clearly	absent	 from	 the	 charge	 ladder	 generated	 upon	 narrowing	 the	 precursor	 ion	selection	 window,	 suggesting	 that	 its	 own	 precursor	 lies	 outside	 of	 the	 narrow	
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precursor	ion	selection	window	(m/z	5995-6005);	a	straightforward	analysis	yields	an	 ionic	mass	 of	 180	 kDa,	 corresponding	 to	 a	 3:1	AT/heparin	 complex	 (see	 black	arrows	in	Figure	2-4).	A	complete	set	of	the	limited	charge	reduction	data	(obtained	by	 moving	 the	 precursor	 ion	 selection	 window	 over	 the	 entire	 m/z	 region	 of	interest)	is	presented	in	the	Supplementary	Material	section.	
2.3.4	Combination	of	limited	charge	reduction	and	ion	mobility	increases	
measurement	throughput	Although	narrowing	down	the	precursor	ion	selection	window	as	a	means	of	limiting	the	number	of	different	 ionic	species	 leads	to	high-quality	MS	data,	where	mass	 assignment	 can	 be	 readily	 (and	 unequivocally)	 made,	 it	 has	 one	 significant	drawback.	 Indeed,	 it	 results	 in	 a	 dramatic	 increase	 of	 the	 overall	 data	 acquisition	time,	 as	a	 significant	number	of	 experiments	are	 required	 to	 cover	 the	entire	m/z	region	 of	 interest	 to	 reveal	 all	 contributors	 to	 the	 unresolved	 ionic	 signal	 in	 the	native	 ESI	mass	 spectrum	 (e.g.,	 it	 would	 require	 300	measurements	 to	 cover	 the	entire	m/z	range	4000-7000	in	native	ESI	mass	spectrum	of	the	AT/heparin	mixture	if	the	width	of	the	precursor	ion	selection	window	were	kept	at	10	u,	as	was	done	to	acquire	 data	 shown	 in	 Figure	 2-4).	 To	 avoid	 this	 clearly	 unacceptable	 data	acquisition	time	scale,	one	may	use	wide	precursor	 ion	selection	windows	for	m/z	regions	where	relatively	modest	spectral	complexity	allows	such	data	to	be	readily	interpreted	 (e.g.,	 m/z	 >	 6500	 in	 Figure	 2-3),	 and	 resort	 to	 narrow	 selection	windows	only	when	necessary	(vide	supra).		Another	possibility	to	increase	the	throughput	without	sacrificing	the	quality	lies	 with	 incorporating	 ion	 mobility	 in	 the	 experimental	 work	 flow.	 Even	 when	
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relatively	 narrow	 precursor	 ion	 isolation	 windows	 are	 used,	 adding	 ion	 mobility	dimension	 provides	 an	 additional	 advantage	 of	 higher	 resolution,	 which	 allows	better	 distinction	 to	 be	 made	 among	 the	 closely	 spaced	 charge-reduced	 species	representing	 different	 precursor	 ions	 (Figure	 2-5A).	 This	 advantage,	 however,	 is	not	critical,	as	the	ion	peaks	populating	the	m/z	region	above	5500	u	in	Figure	2-5A	can	 be	 readily	 distinguished	 from	 another	 even	 without	 taking	 the	mobility	 data	into	 consideration,	 although	 the	 2-D	 data	 presentation	 (using	 both	m/z	 and	 the	mobility	dimensions)	does	allow	the	charge	state	assignment	of	the	product	ions	to	be	verified	by	localizing	on	a	single	diagonal	a	group	of	ions	having	the	same	mass	but	different	number	of	charges	on	a	single	diagonal.	More	importantly,	inclusion	of	the	ion	mobility	step	in	the	measurement	scheme	allows	meaningful	information	to	be	extracted	even	when	a	wide	m/z	window	is	used	for	selecting	the	precursor	ions	(Figure	 2-5B).	 Even	 though	 no	 distinction	 can	 be	 made	 in	 this	 case	 among	 the	charge-reduced	 species	 along	 either	m/z	 or	 the	 drift	 time	 axes	 alone,	 the	 distinct	ionic	 signals	 are	 clearly	discernable	 in	 the	2-D	diagram,	 revealing	 the	presence	of	1:1	 AT/heparin	 complexes	with	 relatively	 short	 heparin	 chains	 (ranging	 from	 4.5	kDa	to	at	least	13.5	kDa).	At	the	same	time,	these	“broad-band”	experiments	provide	substantial	 improvements	 vis-a-vis	 measurements’	 throughput,	 as	 the	 data	acquisition	 time	 for	 a	 single	measurement	 is	 independent	 of	 the	window’s	width	(both	mass	spectra	shown	in	Figure	2-5	were	acquired	within	20	min,	but	a	wider	precursor	 ions	 selection	 window	 allows	 fewer	 experiments	 to	 be	 carried	 out	 to	cover	the	entire	m/z	region	of	interest).	
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2.3.5	Interpretation	of	AT/heparin	mass	spectrum	based	on	the	limited	charge	
reduction	data	Application	 of	 the	 limited	 charge	 reduction	 to	 ions	 selected	 from	 different	regions	 of	 the	 native	 ESI	 mass	 spectrum	 of	 AT/heparin	 mixture	 allows	 various	spectral	features	to	be	readily	assigned	as	contributions	of	complexes	with	different	stoichiometry,	as	well	as	 free	heparin.	The	mass	and	charge	state	ranges	obtained	for	these	species	in	the	course	of	limited	charge	reduction	measurements	allow	the	deconvolution	 of	 the	 unresolved	mass	 spectrum	 of	 the	 AT/heparin	mixture	 to	 be	carried	out	(Figure	2-6).	The	most	 important	assumption	made	here	was	that	 the	distribution	 of	 charges	 for	 ions	 representing	 an	 ATx·heparin	 complex	 at	 each	specific	 stoichiometry	 fits	 normal	 (Gaussian)	 distribution,	which	 had	 been	 shown	before	 to	work	well	with	 homogeneous	 protein	 ions	 generated	 by	 native	 ESI.39-41	However,	 unlike	 homogeneous	 populations	 of	 protein	 ions,	 the	 individual	 charge	states	within	each	ATx·heparin	complex	are	not	expected	to	be	resolved,	prompting	us	 to	model	 the	 entire	population	of	 such	 ions	 as	 a	Gaussian	 curve	 in	 the	 inverse	(z/m)	 space.	The	 initial	 positioning	of	 each	 curve	was	based	on	 the	mass	 spectral	data	 provided	 by	 limited	 charge	 reduction	measurements,	 as	 shown	 at	 the	 top	 of	
Figure	2-6.	This	was	followed	by	supervised	minimization	aiming	at	achieving	the	best	 fit	 of	 the	 sum	 of	 all	 curves	 with	 the	 experimental	 data,	 allowing	 the	contribution	of	each	ATx·heparin	complex	(as	well	as	unbound	heparin)	to	the	total	ion	signal	in	the	mass	spectrum	of	the	AT/heparin	mixture	to	be	determined.	Although	it	may	be	tempting	to	relate	the	relative	abundance	of	each	type	of	complex	 to	 its	 fractional	 concentration	 in	 solution,	 it	 is	 likely	 that	 at	 least	 some	distortion	exists	due	to	the	differences	in	ionization	efficiencies,	which	are	known	to	
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be	influenced	by	a	variety	of	factors	(the	major	one	being	relative	hydrophobicity	of	the	 species	 in	 solution42,43).	 Nevertheless,	 semi-quantitative	 conclusions	 can	 be	made	 on	 the	 influence	 of	 various	 intrinsic	 and	 extrinsic	 characteristics	 on	 the	efficiency	 of	 formation	 of	 protein/GAG	 complex	 formation	 with	 a	 specific	stoichiometry	by	monitoring	the	intensity	change	of	the	corresponding	ionic	signal	in	response	to	variation	of	either	environmental	factors	(e.g.,	solution	ionic	strength,	temperature	 and	 pH)	 or	 the	 binding	 partners’	 characteristics	 (e.g.,	 protein	modifications	 or	 mutations,	 alteration	 of	 GAG	 length	 of	 extent	 of	 sulfation,	 etc.).	Another	 important	 information	 that	 can	 be	 uniquely	 extracted	 from	 the	 limited	charge	 reduction	measurements	presented	 in	 this	work	 is	 the	 range	of	GAG	chain	lengths	 that	 can	accommodate	a	 certain	number	of	proteins	 (such	protein	 loading	information	 is	particularly	valuable	 in	 the	design	of	protein	drug	delivery	systems	utilizing	 GAGs	 as	 scaffolds).	 For	 example,	 the	 1:1	 AT/heparin	 complexes	 (signal	component	colored	in	red	in	Figure	2-6)	incorporate	relatively	short	heparin	chains	(up	 to	 25	 kDa),	 while	 complexes	 with	 higher	 stoichiometry	 use	 notably	 longer	heparin	chains	(up	to	36	kDa	and	49	kDa	for	2:1	and	3:1	complexes,	respectively).	The	 implicit	 assumption	 made	 here	 is	 that	 a	 single	 AT	 molecule	 cannot	accommodate	more	than	a	single	heparin	chain,	which	allowed	us	to	determine	the	stoichiometry	 of	 AT/heparin	 complexes	 based	 on	 their	 masses.	 While	 there	 is	unequivocal	proof	that	AT	has	only	a	single	heparin-binding	site,44,45	other	heparin	clients	may	exhibit	more	promiscuous	behavior	and	accommodate	a	larger	number	of	GAG	chains,	making	it	difficult	to	deduce	the	stoichiometry	of	the	protein/heparin	complex	from	its	mass	alone.	This	problem	may	be	circumvented	by	 introducing	a	
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separation	 step	 (either	 size	 exclusion	 or	 ion	 exchange	 LC)	 in	 the	 experimental	routine	presented	in	this	report	(this	work	is	currently	underway	in	our	laboratory).	Finally,	 the	 ability	 to	 obtain	 information	 on	 charge	 state	 distributions	 of	 ionic	populations	 representing	 various	 protein/GAG	 complexes	 allows	 the	conformational	 stability	 of	 the	 polypeptide	 components	 of	 such	 complexes	 to	 be	evaluated.	 Not	 surprisingly,	 the	 charge	 state	 distributions	 of	 all	 AT/heparin	complexes	observed	 in	 this	work	are	narrow,	 and	 the	 ionic	 charge	density	 is	 low,	suggesting	 that	a	compact	conformation	 is	maintained	 in	solution.21	However,	 this	may	 not	 be	 universally	 true,	 and	 the	 shapes	 of	 charge	 state	 distributions	 of	 ions	representing	polypeptide/GAG	complexes	may	provide	important	clues	vis-à-vis	the	nature	 of	 the	 interaction	 (e.g.,	 binding	 to	 a	 well-defined	 “epitope”	 on	 the	 protein	surface	 vs.	 polyanion/polycation	 interaction	 that	 maximizes	 the	 electrostatic	attraction	by	keeping	both	chains	unfolded,	which	is	likely	to	be	the	case	for	heparin	interaction	with	protamines	or	protamine-inspired	polycations).	Finally,	the	ability	to	determine	the	average	charge	of	ions	representing	a	protein/GAG	complex	raises	a	very	intriguing	question	whether	this	information	can	be	used	to	estimate	physical	dimensions	of	 these	complexes	 in	solution,	an	approach	that	had	been	used	 in	 the	past	to	estimate	the	size	of	globular	proteins	and	protein	complexes,46	and	was	later	extended	to	unfolded	proteins,	including	intrinsically	disordered	species.47	
2.4	Conclusions	Mass	measurements	of	large	highly	heterogeneous	macromolecular	ions	and	their	non-covalent	complexes	traditionally	presented	a	challenge	for	native	ESI	MS;	
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even	though	this	technique	had	been	successfully	used	in	the	recent	past	to	measure	masses	of	very	large	protein	assemblies,	the	best	results	are	usually	obtained	when	working	 with	 highly	 homogeneous	 targets.	 In	 contrast,	 the	 progress	 had	 been	relatively	modest	when	the	analytical	targets	are	(bio)polymers	whose	synthesis	is	controlled	 enzymatically	 or	 semi-synthetically,	 rather	 than	 genetically.	 In	 this	regard,	 heparin	 and	 heparin-like	 GAGs	 constitute	 a	 particularly	 “difficult”	 class	 of	compounds	that	exhibit	truly	intimidating	degree	of	heterogeneity:	it	challenges	the	very	 notion	 of	molecular	mass,	 which	 loses	 its	 clear	 and	 intuitive	meaning	when	applied	 to	 highly	 heterogeneous	 species,	 such	 as	 heparin.	 As	 a	 result,	 analytical	characterization	of	heparin	and	heparin-like	GAGs	(as	well	as	their	complexes	with	client	 proteins)	 were	 traditionally	 focused	 on	 extracting	 characteristics	 averaged	across	the	entire	ensemble;	an	alternative	approach	focuses	on	short	homogeneous	mimetics	as	heparin	surrogates,	which	willingly	sacrifices	the	unparalleled	diversity	of	 intact	 native	 heparin.	 In	 contrast,	 a	 combination	 of	 native	 ESI	 MS	 and	 limited	charge	reduction	in	the	gas	phase	allows	meaningful	information	to	be	obtained	on	individual	 protein/GAG	 complexes,	 including	protein	 loading	 and	 the	 range	of	 the	GAG	 chain	 lengths.	 While	 the	 exhaustive	 characterization	 of	 all	 ionic	 species	contributing	 to	 the	 continuum	 signal	 in	 native	 ESI	 could	 be	 time	 consuming,	introduction	of	ion	mobility	measurements	into	the	experimental	scheme	allows	the	measurements	be	carried	out	in	a	broad-band	mode,	leading	to	a	significant	increase	in	 throughput	 (as	 had	 been	 observed	 in	 other	 instances	when	 utilization	 of	wide	precursor	 ion	 selection	 windows	 increased	 the	 measurement	 throughput48).	 The	analytical	capabilities	of	this	method	of	monitoring	GAG/protein	interactions	will	be	
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expanded	 further	 by	 incorporation	 of	 an	 on-line	 separation	 step	 prior	 to	 ESI	 MS	analysis:	recently	we	demonstrated	that	limited	charge	reduction	can	be	used	in	the	on-line	format	with	ion	exchange	and	size	exclusion	chromatography	(manuscript	in	preparation).	Utilization	of	an	extra	separation	step	that	does	not	compromise	the	integrity	 of	 non-covalent	 associations	 will	 allow	 complex	 GAG/protein	 systems	(where	 two	 or	 more	 different	 proteins	 are	 tethered	 to	 a	 single	 chain)	 to	 be	interrogated	 in	 a	 meaningful	 fashion.	 This	 will	 undoubtedly	 open	 up	 a	 host	 of	exciting	 and	 previously	 unavailable	 opportunities	 to	 study	 interactions	 between	heparin-like	GAGs	and	a	variety	of	their	client	proteins,	a	boon	to	both	fundamental	studies	 of	 GAGs,	 and	 the	 design	 of	 drug	 delivery	 systems	 relying	 on	 GAGs	 as	versatile	scaffolds.			
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Figure	2-1.	ESI	mass	spectra	of	4	µM	AT	solutions	in	30	mM	ammonium	acetate	
(pH	6.0)	acquired	in	the	absence	(grey	trace)	and	the	presence	of	0.03	mg/mL	
intact	heparin	(black	trace).	Charge	states	are	labeled	for	ions	representing	
the	β-glycoform	of	AT	(ionic	species	of	the	α-form	are	labeled	with	circles).		 	
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Figure	2-2.	Ions	generated	by	limited	charge	reduction	of	a	population	of	free	
heparin	ions	whose	m/z	values	are	confined	to	the	m/z	region	3190-3220.	
Colored	arrows	indicate	positions	of	charge	reduced	species	corresponding	to	
precursor	ions	with	different	masses	and	charge	states	whose	m/z	values	fall	
within	the	selection	window.	Asterisk	indicates	an	ionic	peak	that	could	not	be	
assigned	as	a	product	of	charge	reduction	alone	(and,	therefore,	must	
represent	fragment	ions).		 	
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Figure	2-3.	Native	ESI	mass	spectrum	of	the	AT/heparin	mixture	(black	trace)	
and	three	representative	mass	spectra	of	ions	produced	via	limited	charge	
reduction	of	precursor	ions	whose	m/z	values	fall	within	4450-4550	(red),	
5950-6050	(purple)	and	6850-7050	(blue)	m/z	regions.		 	
	 41	
	
	
Figure	2-4.	Limited	charge	reduction	mass	spectra	obtained	using	wide	
(purple)	and	narrow	(cyan)	precursor	ion	selection	window.	The	ionic	species	
labeled	with	A,	B	and	C	represent	resolved	charge-reduced	species	whose	
precursor	ions’	m/z	values	fall	within	both	the	broad	and	the	narrow	selection	
windows	(calculated	masses	are	138.1,	132.1	and	126.1	kDa,	respectively).	
The	black	arrows	indicate	positions	of	several	charge-reduced	species	and	
their	common	precursor	ion	that	had	been	filtered	out	by	switching	for	the	
broad	to	the	narrow	selection	window.		 	
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Figure	2-5.	Mass	spectra	(cyan	traces)	and	ion	mobility	mass	spectra	(2-D	
diagrams)	of	ions	produced	by	limited	charge	reduction	of	precursor	ions	at	
m/z	4500	isolated	using	a	narrow	selection	window	(window	width	10	u,	
panel	A)	and	a	wide	selection	window	(window	width	100	u,	panel	B).	The	
resolved	charge-reduced	species	are	circled	and	their	masses/charge	states	
labeled.		 	
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Figure	2-6.	Extraction	of	contributions	of	ATx·heparin	complexes	to	the	total	
ionic	signal	in	the	native	ESI	mass	spectrum	of	AT/heparin	mixture	based	on	
the	results	of	limited	charge	reduction	measurements.	The	number	of	AT	
molecules	in	each	ionic	species	is	indicated	on	each	curve;	the	black	line	is	the	
summation	of	all	individual	contributions	(best	fit	to	the	experimental	data	
shown	in	gray).	The	colored	bars	at	the	top	of	the	graph	show	m/z	ranges	for	
each	species	provided	by	limited	charge	reduction	measurements.	
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CHAPTER	3	
	
ION-MOBILITY	MASS	SPECTROMETRY	COUPLING	WITH	LIMITED	CHARGE	
REDUCTION	REVEALS	DISTINCT	MODELS	OF	INTERACTION	BETWEEN	
HEPARIN	AND	PROTAMINE	SULFATE†	
3.1	Introduction	Heparin	 as	 one	 of	 the	 best	 known	 glycosaminoglycans	 (GAG)	 is	 the	 most	negatively	charged	natural	polymer	to	our	knowledge	with	mass	ranging	from	3kDa	to	23kDa	 (Figure	 3-1A)1.	 It	 can	 interact	with	 a	broad	 range	of	proteins	 including	many	 coagulant	 factors2	 and	 other	 clinically	 relevant	 binding	 partners.	 Heparin	(usually	 in	the	form	of	a	heparinase	digestion	mixture	with	 low	molecular	weight)	are	 widely	 used	 in	medicine	 as	 an	 anticoagulant.3	 Protamine	 is	 a	 family	 of	 small	arginine-rich	proteins	 (50-100	amino	acids)	 synthesized	 in	eukaryotic	 sperm	cells	for	 packaging	 chromosomal	 DNA4	 The	 highly	 dense	 positive	 charge	 also	 allows	protamine	to	potentially	 interplay	with	heparin,	 thus	one	derived	drug,	protamine	sulfate,	also	simplified	as	protamine	in	this	paper,	has	been	widely	used	as	a	natural	antidote	of	heparin,	for	instance,	during	the	closing	of	a	surgery	in	order	to	restore	the	 level	 of	 platelet	 aggregation	 that	 has	 been	 originally	 suppressed	 by	 low	molecular	 weight	 heparin5,6.	 The	 interaction	 between	 heparin	 and	 protamine	 has	also	been	utilized	for	making	heparin	sensors7,	protein	therapeutic	delivery	systems	and	 tissue	 engineer	 scafolds8,9.	 The	 sequence	of	 protamine	 is	 genetically	 encoded,	varying	 in	 different	 species	 (Figure	 3-1B).	 It	may	 result	 in	 alternative	 secondary																																																									†	This	entire	chapter	with	be	submitted	as	a	manuscript	for	publication	after	further	edition.	
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structures	and	affinity	with	heparin.	A	complete	analysis	of	above	information	has	a	practical	 value	 in	 the	 sense	 that	 quality	 control	 and	 comparability	 study	 can	 be	achieved	 for	 the	 protamine	 produced	 from	 different	 sources	 and	 batches.	 Some	techniques	 for	 particle	 size	 analysis	 (e.g.	 dynamic	 light	 scattering	 and	 analytical	ultracentrifugation)	have	been	proved	to	be	a	valuable	tool	to	probe	the	behavior	of	protamine	 and	 heparin	 interaction10.	 However,	 these	 methods	 were	 limited	 to	estimate	 the	 size	 of	 particles	 in	 nanoscale	 (with	 diameter	 30~60nm)	 and	 it	 lacks	accuracy	 for	approaching	stoichiometry	when	 the	complex	 is	 initiated	 in	 the	early	stage.	And	routine	structural	characterization	 tools	 (e.g.	X-ray	crystallography	and	nuclear	magnetic	 resonance),	 although	can	 create	models	 for	protamine	 itself	 and	protamine/DNA	 complex11,12,	 is	 very	 challenge	 to	 solve	 a	 meaningful	 model	 of	protamine/heparin	 complex.	 One	 reason	 is	 that	 these	 tools	 have	 low	 tolerance	 of	heterogeneity13	 in	 a	 sample	 like	 protamine/heparin	 mixture,	 where	 extensively	variable	sulfation	patterns	of	heparin	and	diverse	sequence	of	protamine	may	give	rise	to	many	species	with	different	stoichiometry	and	structure.	Traveling	wave	ion-mobility	mass	spectrometry	(TWIM-MS)	has	been	widely	used	 in	 mass	 analysis	 and	 structural	 characterization	 of	 macromolecules.	Measurement	of	arrival	time	provides	information	correlated	to	the	physical	size	of	the	 ionized	 molecules.	 Intriguingly,	 it	 can	 be	 directly	 performed	 to	 resolve	 the	components	in	a	sample	containing	multiple	species,	such	as	a	polymer	with	broad	mass	 distribution,	 or	 a	 mixture	 of	 protein	 oligomers	 differing	 at	 the	 number	 of	subunits	and	topology14,15.	However,	TWIM-MS-based	approach	has	been	limited	to	the	 well-resolved	 species	 whose	 mass	 and	 charge	 state	 can	 be	 determined	
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accurately	for	the	purpose	of	collision	cross	section	(CCS)	calculation.	And	therefore	a	direct	CCS	determination	 is	 impossible	when	analytes	are	poorly	resolved	under	native	 condition	 such	 as	 glycosylated	 proteins	 and	 most	 likely	 in	 the	 case	 of	protamine	and	heparin	complexes.	Previously,	 we	 reported	 that	 electron	 transfer-induced	 limited	 charge	reduction	(LCR)	of	a	selected	ionic	population	was	an	unparalleled	solution	in	order	to	 decrease	 the	 bias	 of	 charge	 state	 assignment	 caused	 by	 peak	 convolution	 in	 a	mass	 spectrum	 acquired	 from	 heterogeneous	 samples	 such	 as	 glycoprotein16,	protein	 complex17	 and	aggregation18.	We	 recently	 reported	another	 case	with	 this	technique	 to	 characterize	 stoichiometry	of	 the	complexes	 formed	by	antithrombin	and	 unfractionated	 heparin	 under	 the	 native	 condition.	 Without	 doing	 limited	charge	 reduction,	 the	 mass	 spectrum	 was	 fully	 unresolved	 and	 only	 displayed	several	 bad-shaped	 ionic	 clusters	 with	 nearly	 a	 continuous	 m/z,	 because	 of	insufficient	 desolvation	 and	 extensive	 degree	 of	 ammonium	 ion	 adduct19.	Nevertheless,	 limited	charge	reduction	allowed	us	to	resolve	all	species	existing	 in	the	 same	 isolation	 window	 and	 reconstruct	 the	 distribution	 of	 the	 complexes	through	placing	isolation	window	across	the	entire	m/z	range.	In	the	same	work,	we	also	 demonstrated	 that	 use	 of	 a	 post-LCR	 ion-mobility	 separation	 dramatically	enhanced	 the	 resolution	 of	 charge-reduced	 species.	 The	 different	 charge-reduced	populations	were	readily	separated	in	the	drift	time	domain	even	though	the	mass	spectrum	itself	is	very	convoluted	when	the	isolation	window	is	broad.		In	 the	 current	 paper	we	 investigated	 a	mixture	 of	 protamines	 and	 heparin	oligosaccharides	 under	 the	 native	 condition	 using	 TWIM	 coupling	 with	 limited	
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charge	 reduction.	 Our	 data	 provides	 novel	 insights	 of	 stoichiometry	 and	conformation	 for	 the	protamine/oligosaccharide	 complexes	during	 the	 early	 stage	of	the	particle	formation.	
3.2	Experimental	
3.2.1	Materials	Protamine	 sulfate	 was	 provided	 by	 United	 States	 Pharmacopeia.	 Heparin	oligosaccharide	 isolated	 through	 size	 exclusion	 chromatography	 was	 purchased	from	 Iduron	 (UK).	 We	 used	 the	 fraction	 predominantly	 consisting	 of	 the	oligosaccharide	with	twenty	saccharide	units,	thus	referred	as	dp20.	Protamine	and	dp20	powder	were	dissolved	 into	distilled	water	 (Millipore,	MA)	 initially	 to	make	stock	solutions	then	diluted	as	10mg/ml	with	150mM	ammonium	acetate	at	pH=6.9.	We	 mixed	 protamine	 and	 dp20	 at	 1:1	 ratio	 (g/g)	 and	 directly	 used	 them	 for	chromatography	 analysis	 or	 native	 mass	 spectrometry	 without	 extra	 time	 for	incubation.	
3.2.2	Online	Ion-exchange	Chromatography-Native	Mass	Spectrometry	Ion-exchange	 chromatography	 was	 carried	 on	 using	 Agilent	 1200	 HPLC	system	 equipped	 with	 a	 weak	 cation	 exchange	 column	 ProPac-100	 (Thermo	Fischer).	 The	 column	 was	 equilibrated	 with	 10mM	 ammonium	 bicarbonate	 at	pH=8.5	 prior	 to	 sample	 injection.	 Gradient	 elution	 was	 applied	 by	 increasing	 the	concentration	of	ammonium	bicarbonate	up	to	500mM	at	the	same	pH.	No	extra	salt	was	 added	 into	 the	mobile	phase.	A	7T	Bruker	 SolariX	FT-ICR	mass	 spectrometer	
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was	 used	 for	 online	 mass	 spectrometry	 analysis.	 To	 get	 better	 ionization	performance,	 the	 inlet	 flow	 for	 electrospray	 source	 is	 reduced	 to	 20µl/min	 via	 a	splitter	after	the	fluid	pass	through	the	column.	Data	acquisition	was	triggered	with	Hystar	software.	
3.2.3	Ion-Mobility-Mass	Spectrometry	Coupling	with	Limited	Charge	
Reduction	The	protamine	dp20	mixture	was	 introduced	to	the	gas	phase	using	Synapt	G2S	equipped	with	nanospray	source.	 In	order	 to	create	a	gentle	source	condition	with	 well	 ionization	 efficiency,	 capillary	 voltage	 was	 1.5	 kV,	 source	 temperature	remained	at	80	°C,	cone	voltage	was	10	V.	Limited	charge	reduction	was	carried	on	basically	 following	a	modified	procedure	for	regular	electron	transfer	dissociation.	Briefly,	 a	 narrow	 ionic	 population	within	 specific	m/z	window	was	 isolated	using	quadrupole	first,	LM	resolution	was	set	to	3.9	and	HM	resolution	was	set	to	12.	Then	electron	 transfer	 reagent	 1,3-dicyanobenzene	 was	 introduced	 into	 the	 trap	 to	interact	with	 analyte	 ions	 and	 induce	 their	 limited	 charge	 reduction.	 The	 vacuum	and	 traveling	 wave	 height	 in	 the	 trap	 cell	 were	 optimized	 so	 that	 a	 remarkable	charge	reduced	populations	can	be	observed.	For	ion-mobility	separation	of	charge	reduced	 ions,	 IMS	 wave	 velocity	 and	 height	 were	 set	 to	 300	 m/s	 and	 25	 V,	respectively;	vacuum	reached	3.5	mbar	in	helium	cell	and	2.5	mbar	in	IMS	cell.	Trap	DC	bias	was	ramped	to	35	V	in	order	to	achieve	sufficient	ion	transmission.	
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3.2.4	CCS	Calibration	A	couple	of	standard	proteins	with	small	CCS	and	mass	value	including	native	cytochrome	C,	BLG	and	denatured	ubiquitin	was	run	at	the	same	condition	as	for	the	protamine	dp20	mixture.	Calibration	curve	was	created	based	on	 IM-MS	 following	the	regular	protocol	described	in	reference	(15).	
3.2.5	Data	Analysis	Online	 IXC-MS	 data	 were	 processed	 using	 DataAnalysis	 software	 (Bruker	Daltonics)	 and	 LCR-IM-MS	 data	 were	 analyzed	 using	 Masslynx	 and	 Driftscope	software	(Waters).	CCS	plot	fitting	was	done	using	Origin	Pro	(Northampton,	MA).	
3.3	Results	and	Discussion	
3.3.1	Electrostatic	Interaction	Between	Heparin	and	Protamine	Can	be	Probed	
using	WCX-MS	Online	WCX-MS	enables	 a	 real-time	monitoring	of	 eluents	 as	 ionic	 strength	increases,	 although	 the	 use	 of	 ammonium	 bicarbonate	 may	 not	 have	 the	 same	performance	of	separation	as	sodium	chloride	does.	We	observed	that	dp20	eluted	immediately	 before	 the	 gradient	 elution	 step	 started,	 indicating	 that	 dp20	 was	negatively	charged	at	pH	8.5	and	was	not	retained	on	the	column	(Figure	3-2,	 the	top	panel).	In	contrast,	protamine	itself	only	eluted	at	high	ionic	strength.	Extracted	ion	chromatogram	rendered	two	fractions	 in	the	protamine	sample	based	on	their	retention	times	(Figure	3-2,	the	bottom	panel,	left	column).	The	late	eluted	fraction	represented	 the	protamine	 species	with	higher	mass	 and	more	positively	 charged	residues.	However,	the	retention	of	protamine	on	the	column	was	fully	eliminated	in	
	 52	
the	presence	of	dp20	(Figure	3-2,	 the	middle	panel).	We	found	protamine	species	with	higher	mass	were	eluted	together	with	dp20.	The	result	clearly	suggested	that	a	 charge	 neutralization	 and	 an	 interaction	 occurred	 between	 polyanions	 and	polycations,	although	we	did	not	observe	ionic	signals	corresponding	to	the	mass	of	protamine	 dp20	 complexes	 (>9000Da)	 under	 the	 applied	 harsh	 desolvating	conditions	 chosen	 for	 the	 online	 experiment.	 Interestingly,	 the	 signals	 of	 several	protamine	species	with	lower	masses	(like	the	one	shown	in	the	yellow	trace	in	the	bottom	 panel	 of	 Figure	 3-2)	 were	 invisible.	 That	 is	 perhaps	 because	 the	 ionic	signals	of	 less	abundant	species	were	suppressed	during	 ionization	 if	 they	are	not	separated	by	ion-exchange	chromatography.	
3.3.2	Characterization	of	Complexes	Formed	by	Protamine	and	dp20	using	
Native	Mass	spectrometry	with	Limited	Charge	Reduction	To	examine	whether	the	observed	charge	neutralization	can	be	attributed	to	a	direct	 interaction	between	protamine	and	dp20,	we	analyzed	 the	mixture	under	native	 conditions	 using	 mass	 spectrometry.	 The	 mass	 spectrum	 of	 the	 mixture	displayed	 extensive	 ionic	 signals	 but	 only	 a	 small	 portion	 of	 them	were	 partially	resolved	(below	1500	m/z)	and	they	corresponded	to	the	unbound	dp20.	All	 ionic	signals	from	m/z=1500	to	m/z=3000	were	completely	unresolved	and	suggested	an	ionic	 cluster	with	 signals	 at	 every	 single	m/z	 value	 (as	 shown	 in	 the	 top	panel	 of	
Figure	 3-3).	 To	 measure	 the	 mass	 of	 the	 cluster,	 we	 isolated	 precursor	 ions	 at	m/z=2300	and	induced	limited	charge	reduction.	A	series	of	well-resolved	product	ions	appeared	in	the	m/z	region	from	2500	to	5000.	Interpretation	of	those	charge-reduced	 ions	 was	 done	 by	 following	 the	 same	 approach	 described	 in	 previous	
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work.19	The	intensity	of	charge-reduced	ions	was	sufficient	 for	us	to	assign	charge	states	 based	 on	 the	 spacing	 between	 two	 correlated	 peaks	 and	 to	 calculate	 their	mass	then.	As	a	result,	three	ionic	species	with	different	mass	were	characterized	in	the	isolated	ionic	population	(as	indicated	in	the	middle	panel	of	Figure	3-3).	It	was	straightforward	to	determine	the	6,900Da	and	9,200Da	species	to	be	two	complexes	of	 protamine	 and	 dp20	 at	 1:1	 ratio	 based	 on	 the	 individual	mass	 range	 for	 dp20	(3,360-5,760Da)	and	for	protamine	(3,000-4,500Da),	respectively.	The	third	mass	at	11,500Da	 must	 be	 a	 ternary	 complex	 however	 we	 cannot	 assure	 the	 ratio	 of	protamine	and	dp20.	Obviously,	 either	 the	 complex	with	a	 single	protamine	chain	and	 two	dp20	chains	or	 the	one	with	a	dp20	chain	and	 two	protamine	chains	can	both	show	masses	of	11,500Da.	This	is	a	common	issue	that	we	cannot	just	base	on	the	mass	value	 itself	 to	assign	a	complex	stoichiometry	when	the	 theoretical	mass	ranges	of	two	heterogeneous	binders	are	largely	overlapping.	
3.3.3	Ion-Mobility	Separation	and	CCS	measurement	of	Charge-Reduced	
Product	Ions	First,	 we	 investigated	 a	 precursor	 ion	 with	 relative	 low	m/z	 (1600)	 using	limited	 charge	 reduction.	As	 shown	 in	Figure	 3-4,	we	observed	 five	distinct	 ionic	populations	 in	 the	 ion	mobility	 mass	 spectrum.	 The	 ionic	 signals	 within	 the	m/z	region	from	1490	to	1650,	originated	from	the	isolated	precursor,	were	divided	into	two	 populations	 in	 the	 drift	 time	 domain,	 centering	 at	 4.3ms	 and	 5.18ms	respectively.	They	were	 subjected	 to	 limited	 charge	 reduction	and	 then	generated	other	three	populations,	being	further	separated	according	their	drift	times	and	m/z	values.	By	a	manually	deconvoluting	those	peaks,	we	can	promptly	find	two	sets	of	
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charge	 ladders	 corresponding	 to	 the	 ions	 with	 molecular	 weight	 4800Da	 and	6400Da	 respectively	 (labeled	 in	 different	 colors	 and	 summarized	 in	 Figure	 3-4).	Clearly,	 the	 involvement	 of	 ion-mobility	 increased	 the	 resolving	 power	 for	 the	different	 ionic	 species	 by	 providing	 an	 extra	 dimension	 of	 separation.	 It	was	 also	noted	that	the	peaks	of	both	precursor	ions	and	charge	reduced	product	ions	in	ion-mobility	mode	remained	broaden	and	displayed	more	signals	below	the	desired	m/z	values	 (set	 in	 the	quadrupole)	 compared	 to	 those	 in	 the	 spectrum	acquired	when	ion-mobility	separation	was	off.	These	tailing	signals	were	probably	induced	by	the	shedding	of	sulfate	group	under	an	enhanced	DC	bias	voltage	applied	in	the	trap	cell,	which	was	 required	 for	 a	 sufficient	 ion	 transmission	 through	 the	 ion-mobility	 cell	against	the	buffering	nitrogen	gas.		Next	 we	 calculated	 the	 collision	 cross	 sections	 for	 each	 observed	 ionic	population	(listed	in	the	table	under	Figure	3-4).	To	be	noted,	a	precursor	ion	and	its	multiple	charge-reduced	states	had	very	intimate	CCS	values	(standard	deviation	<	0.2)	suggesting	that	the	physical	size	of	a	polymer	ion	remained	the	same	during	the	 charge-stripped	 process	 in	 the	 gas	 phase.	 Therefore,	 the	 similarity	 of	 CCS	between	different	charge	states	can	be	a	criterion	for	checking	whether	correct	ionic	species	were	picked	up	as	one	charge	ladder	representing	the	same	precursor	ion.	
3.3.4	Data	from	Specific	m/z	Regions	Revealed	Distinct	Species	with	the	Same	
Mass	To	 identify	 the	 complexes	 in	 the	mixture,	 the	 precursor	 ions	 at	 other	m/z	value	 across	 the	 entire	 region	 where	 ionic	 signals	 displayed	 were	 isolated	 and	subjected	 to	 limited	 charge	 reduction.	 We	 compared	 the	 IM-MS	 at	 precursor	 at	
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m/z=2400	 with	 the	 mass	 spectrum	 without	 ion	 mobility	 at	 the	 m/z=2300	 (the	bottom	two	panels	of	Figure	3-3).	This	small	discrepancy	on	precursor	m/z	value	selection	(i.e.	2300	vs.	2400)	was	kept	only	to	provide	better	alignment	of	peaks	due	to	 the	 consideration	 of	 the	 tailing	 in	 the	 spectrum	 acquired	 in	 the	 ion-mobility	mode.	 From	 the	 ion-mobility	mass	 spectrum,	 some	 additional	 information	 can	 be	extracted.	First,	a	new	charge	ladder	representing	a	13,800Da	precursor	ion	with	+6	charge	 state	 was	 exclusively	 identified	 in	 the	 ion-mobility	 mode.	 We	 can	 clearly	noticed	 that	 its	 reduced	 charge	 states	 (+4ß6)	 (representing	 the	 +4	 product	 ion	reduced	from	the	+6	precursor	ion)	was	thoroughly	overlapped	in	the	m/z	domain	with	 the	 product	 ions	 reduced	 from	 another	 precursor	 charge	 state	 (+2ß3)	 of	6,900Da,	however	these	two	species	can	be	separated	in	the	drift	time	domain	due	to	 the	 remarkable	 differences	 in	 charge.	 Similarly,	 IM-MS	 enabled	 the	 distinction	between	two	ionic	populations,	(+3ß6)	of	13,800Da	and	(+2ß4)	of	9,200Da.	Although	 significantly	 driven	 by	 charge	 difference	 between	 individual	populations,	 the	 IM-based	 separation	 can	 also	 distinguish	 two	 populations	 with	differences	in	physical	size	(CCS	values)	when	they	had	the	same	mass	and	charge.	Indeed,	 for	 the	11,500Da	species,	 two	populations	of	charge	series	presented	with	different	 drift	 time	 values,	 corresponding	 to	 two	 species	with	 the	 same	mass	 but	different	CCS	values.	We	also	observed	two	populations	of	distinct	CCS	for	multiple	charge	 states	 of	 13,800Da	 ions.	We	 hypothesized	 that	 the	 second	 population	was	not	 converted	 from	 the	 other	 in	 the	 gas	 phase.	 To	 verify	 this	 hypothesis,	 we	investigated	 the	same	charge	state	+3ß4	generated	 from	 four	different	precursors.	As	illustrated	in	Figure	3-5A,	it	was	that	the	population	with	larger	CCS	(referred	to	
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as	 population	B)	 did	not	 appear	 until	 the	mass	 reached	 a	 value	 between	8,800Da	and	9,600Da	and	 then	 the	relative	abundance	of	B	continued	 to	grow	as	 the	mass	increases.	This	observation	strongly	suggested	that	the	population	B,	representing	a	conformation	 or	 stoichiometry	 differing	 from	 A,	 can	 only	 formed	 over	 a	 specific	mass	range,	reflecting	the	presence	of	the	species	in	the	solution.	We	also	observed	that	the	population	A	had	more	tailing	signals	than	the	population	B,	suggesting	that	the	population	A	was	composed	of	higher	degree	of	heparinoid	component,	which	offers	 more	 opportunity	 of	 mass	 decrease	 related	 to	 sulfate	 group	 shedding.	 For	example,	the	population	A	could	represent	the	complex	with	one	protamine	and	two	chains	 of	 dp20,	 and	 the	 population	 B	 could	 represent	 the	 complex	 with	 two	protamine	 and	 one	 dp20	 because	 the	 theoretical	 minimal	 mass	 of	 the	 latter	stoichiometry	 is	 about	 9360Da	 (3000+3000+3360)	 and	 just	 falls	 in	 the	 proposed	mass	range	determined	upon	above.	 In	a	conclusion,	 ion-mobility-enabled	analysis	on	 limited	 charge	 reduction	 data	 provides	 additional	 hints	 on	 the	 potential	stoichiometry	and	conformation	of	the	complex.		
3.3.5	Comprehensive	Analysis	of	Stoichiometry	and	Conformation	based	on	
CCS-Mass	Relationship	This	approach	only	focused	on	the	well-resolved	charge-reduced	populations	to	extract	 the	CCS,	mass	and	charge	 information	of	 species	 that	 coexist	within	 the	precursor	 isolation	 windows	 and	 overlooked	 the	 ions	 without	 good	 separation,	including	 the	precursor	 ions	 themselves.	For	 the	precursors	at	m/z=2400	(Figure	
3-3,	 the	bottom	panel)	as	an	example,	 the	 ionic	signals	 falls	within	2200-2400	are	very	 convoluted	 thus	we	were	 unable	 to	 precisely	 extract	 the	 drift	 time	 value	 for	
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each	 populations.	 One	 remaining	 questions	 is	 whether	 the	 CCS	 is	 unique	 for	 a	specific	ion	and	not	related	to	the	charge	state	of	precursor.	To	elucidate	this	point,	we	 compared	 the	 CCS	 of	 the	 same	 ion	 generated	 from	 three	 different	 charge	reduction	 processes	 in	 the	 gas	 phases,	 presented	 in	 Figure	 3-5B.	 For	 a	 specific	molecule	 of	 12,000Da,	 the	 +3	 charge	 ion	 (m/z=4000)	 can	 be	 reduced	 from	 three	precursor	ions	with	different	charge	states	+6,	+5,	+4	(see	the	ionic	populations	of	at	m/z=2000,	 2400,	 3000	 respectively)	 and	 all	 of	 these	 +3	 products	 produced	consistent	 CCS	 values	 (about	 11.16nm2)	 no	 matter	 what	 precursor	 it	 was	 born	from),	 indicating	 that	 they	 represented	 the	 same	 specie	 in	 terms	 of	 mass	 and	stoichiometry.	The	consistency	of	CCS	also	happened	on	+4	charge	 ions	except	 for	the	 +4	 precursor	 itself,	 of	 which	 the	 CCS	 is	 not	 available	 due	 to	 the	 convoluted	signals	fallen	within	the	selection	window.	These	observations	strongly	suggests	an	universal	conclusion	that	if	a	molecule	is	ionized	to	different	positive	charge	states,	the	CCS	of	the	ion	at	charge	state	n	is	identical	to	the	CCS	of	the	ion	at	(n+i)	charge	state	when	it	is	reduced	to	charge	state	n	in	the	gas	phase.	In	another	word,	the	CCS	of	 one	 charge	 state	 is	 relatively	 independent	 to	 the	 pathway	 in	 which	 the	 ion	 is	generated.	Besides	in	the	case	of	complexes	formed	by	protein	and	linear	polymer,	this	 conclusion	 has	 also	 been	 validated	 for	 other	 types	 of	macromolecule	 such	 as	native	single	proteins	 including	albumin	and	β-lactoglobulin	 (data	not	shown)	and	denatured	ubiquitin20.	Because	the	mass	and	CCS	of	a	complex	were	 independent	 to	 the	displayed	charge	states,	we	can	plot	the	CCS	values	of	all	available	ions	versus	their	masses	to	elucidate	 the	 relation	 between	 stoichiometry	 distribution	 and	 the	 mass	 of	 the	
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complex,	 as	 shown	 in	 Figure	 3-6,	 where	 the	 two	 ions	 with	 the	 same	 mass	 but	significant	difference	on	CCS	values	(such	as	population	A	and	B	in	Figure	3-5A)	are	in	different	colors.	All	of	those	data	points	were	fitted	by	three	individual	trends,	in	which	the	CCS	value	increases	monotonically	as	mass	 increases.	The	first	curve	on	the	 bottom	 covers	 a	 relatively	 low	 and	 narrow	mass	 range	 (5,000Da-7,000Da).	 It	may	represent	unbound	dp20	and	dp20	non-specifically	binding	with	contaminant	molecules	(such	as	PEG).	Because	dp20	is	a	chain	with	fixed	number	of	saccharides,	the	CCS	increase	can	only	be	attributed	to	number	of	sulfate	group	(or	ammonium	adduct)	 increasing.	 The	 enhanced	 repulsion	 between	 negatively	 charged	 sulfate	groups	makes	 the	 chain	 less	 compact.	 The	 other	 two	 curves	 represent	 protamine	and	 dp20	 complexes.	 Interestingly,	 based	 on	 the	 wide	 mass	 range	 of	 the	 middle	curve	(6,000	–	24,000	Da),	it	may	be	a	combination	of	multiple	stoichiometries.	The	same	types	interpretation	of	IM-MS	data	can	be	seen	in	previous	IM-MS	study	on	the	mechanically	interlocked	polymers	mixture,	where	the	complexes	contain	a	polymer	chain	with	variable	mass	and	a	number	of	macrocycles.21	Therefore,	based	on	 the	experimental	mass	 range,	we	 hypothesize	 that	 the	middle	 trend	 is	 the	 protamine	heparin	1:1,	1:2	and	1:3	complexes	and	the	top	trend	is	the	protamine	heparin	2:1	and	3:1	 complexes.	The	 rationale	of	 this	 assignment	 can	be	verified	 through	 their	potential	structure	features,	which	is	discussed	as	follow.	There	are	several	studies	that	suggested	that	certain	types	of	protamine	has	an	irregular	helical	structure	with	all	charged	arginine	side	chains	toward	outside22.	An	X-ray	 crystallography12	 and	NMR11	 study	also	 revealed	 that	 the	 side	 chains	on	the	 protamine	 helix	 can	 interact	with	 the	 grooves	 of	 double	 strand	 nucleic	 acids.	
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Another	 recent	 molecular	 dynamic	 study	 illustrated	 the	 interface	 between	protamine	 and	 heparin23.	 All	 these	 data	 imply	 that	 a	 protamine	molecule	 is	 very	compact	compared	to	a	dp20	molecule	with	the	same	mass.	Therefore	two	different	models	regarding	how	protamine	and	dp20	can	form	complexes	are	proposed	upon	the	two	trends	(in	orange	and	cyan	in	Figure	3-6)	respectively.	One	model	contains	one	or	two	protamine	as	the	building	center	and	all	dp20	chains	wrapping	around	the	 protamine	 core.	 The	 second	 model	 contains	 multiple	 protamine	 molecules	bridged	by	one	or	two	heparin	chains.	Obviously	the	model	II	has	a	more	extended	conformation	(as	shown	 in	 the	cartoon	of	Figure	 3-6).	Both	model	 I	and	model	 II	may	 represent	 the	 early	 stage	 of	 the	 growth	 of	 protamine/heparin-involved	particles	 at	 various	 ratios	 of	 mixture.	 And	 they	 can	 only	 coexist	 when	 the	concentration	of	protamine	and	dp20	is	low.	If	we	keep	increasing	the	concentration	of	either	on	or	both,	it	will	induce	the	formation	of	larger	complex,	giving	rise	to	an	insoluble	aggregation	eventually.	In	model	I,	the	complex	can	grow	large	under	the	shielding	 from	 excess	 amount	 of	 dp20.	Model	 II	 is	 favored	when	 protamine	 is	 in	excess.	However	the	extended	structure	of	model	II	is	quite	unstable	and	it	does	not	allow	 the	 complex	 to	 expand	 too	 much,	 otherwise,	 the	 hydrophobic	 surface	 of	protamine	may	easily	facilitate	precipitation	immediately24.	
3.4	Conclusions	Native	ESI-IM-MS	provides	an	elegant	means	to	probe	the	topology	of	small	protein	units	aggregates,	such	as	the	discovery	of	the	various	models	of	β-amyloid	related	 complex	 formation,25	 however	 it	 is	 not	 straightforward	 to	 apply	 this	
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approach	to	analysis	of	a	heterogeneous	systems.	We	divided	the	task	of	dissecting	entire	 ionic	 cluster	 into	multiple	 small	 portions,	 only	 focusing	 on	 the	 ions	 falling	within	a	narrow	isolation	window.	Through	identifying	and	recording	mass,	charge	and	CCS	(and	the	relative	abundance	for	a	validation	purpose)	for	all	populations	in	the	 small	 portion	 of	 cluster	 using	 limited	 charge	 reduction,	 we	 can	 finally	reconstruct	a	complete	picture	depicting	the	distribution	of	each	type	of	complexes	from	 the	 giant	 unresolved	 cluster.	 This	 limited	 charge	 reduction	 is	 the	 only	“magnifying	 scope”	 that	 allows	 us	 to	 look	 at	 a	 fully	 unresolved	 spectrum	 in	 a	meaningful	way.		Electron	transfer	induced	charge	reduction	occurs	very	efficiently	in	proteins	and	 other	 ions	 with	 higher	 positive	 charges	 without	 creating	 significant	fragmentation.	 Unlike	 proteins,	 heparin-involved	 protamine	 cannot	 attract	 ample	electrons	 due	 to	 Coloumb’s	 force	 and	 it	 would	 be	 difficult	 to	 generate	 adequate	charge-reduced	states	that	will	be	utilized	for	accurate	mass	and	charge	assignment.	And	the	measurement	of	the	CCS	for	charge-reduced	populations	may	fill	this	gap	by	providing	an	extra	criterion	to	examine	the	initial	charge	state	assignment.	Another	unique	 property	 of	 protamine	 dp20	 complex	 is	 that	 its	 lower	 charge	 state	 has	 an	enlarged	CCS	in	most	cases,	differing	from	what	we	previously	learned	from	studies	on	proteins,	which	follows	an	opposite	law	that	the	CCS	gets	smaller	when	charge	is	reduced20,26.	 One	 possible	 reason	 is	 that	 the	 electrons	 initially	 transferred	 to	 the	complex	 will	 release	 part	 of	 the	 GAG	 chain	 wrapped	 on	 the	 protamine	 and	 the	increased	repulsion	between	highly	dense	negative	charges	of	GAG	makes	the	chain	
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more	 extended,	 if	 we	 assume	 the	 conformation	 of	 GAG	 chain	 makes	 the	 major	contribution	to	the	CCS	of	the	entire	complex.	Although	we	tried	to	correlate	the	CCS	values	to	some	structure	models,	we	are	aware	of	that	we	would	never	build	a	robust	structure	model	without	other	 in	
silico	modeling	approaches	such	as	molecular	dynamics	simulation	as	well.	We	can	regardless	 treat	 the	 CCS-mass	 profile	 as	 a	 fingerprint,	 which	 records	 unique	information	 in	 terms	 of	 the	 distribution	 of	 different	 types	 of	 complexes	 in	 the	solution.	 By	 monitoring	 the	 CCS-mass	 fingerprint	 in	 response	 to	 the	 change	 of	experimental	parameters	(e.g.,	the	ratio	of	mixture	and	the	length	of	saccharide)	and	the	 conditions	 of	 the	 solution	 (e.g.,	 ionic	 strength	 and	 pH),	 we	 can	 evaluate	 the	interactions	between	protamine	and	heparin,	which	is	critical	to	both	basic	studies	on	 mechanism	 of	 protamine/heparin	 aggregation	 and	 the	 practical	 applications	such	 as	 design	 of	 protamine-heparin	 based	 delivery	 system	 and	 method	development	for	quality	control	or	comparability	study	in	the	filed	of	pharmaceutics.	In	 addition,	 the	 approach	 we	 described	 in	 this	 chapter	 can	 be	 applied	 to	 other	heterogeneous	system	for	structural	characterization.		 	
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Figure	3-1.	General	structure	of	heparin	and	protamine.	(A)	Template	of	low	
molecular	weight	heparin.	The	red	color	indicates	where	the	modifications	
(acetylation	and	sulfation)	perhaps	occur.	(B)	The	primary	structure	of	
protamine	sulfate.	It	is	a	mixture	of	subtypes	P1	to	P4,	encoded	in	different	
genes.		 	
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Figure	3-2.	Online	WCX-MS	of	dp20	alone	(top),	dp20	in	the	presence	of	
protamine	(middle)	and	protamine	alone	(bottom).	UV	traces	and	base	peak	
chromatogram	are	shown	in	the	left	column.	The	mass	spectra	of	analytes	
were	shown	in	the	right	column	are	the	average	of	scans	within	time	windows	
indicated	by	the	arrows	in	the	left	column.	The	asterisk	sign	indicates	
contaminant	(PEG)	peaks.		 	
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Figure	3-3.	Top:	mass	spectrum	without	incorporating	ion	isolation;	Middle:	
mass	spectrum	for	limited	charge	reduction	with	precursor	ion	selection	at	
m/z=2300;	Bottom:	ion	mobility	mass	spectrum	for	the	limited	charge	
reduction	with	precursor	ions	selection	at	m/z=2400.	The	number	in	the	
basket	indicates	how	many	species	were	observed.	 	
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Figure	3-4.	Analysis	of	charge	reduced	species	for	the	precursor	selected	at	
m/z=1600.		 	
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Figure	3-5.	(A)	Ion	mobility	spectra	(drift	time	v.s.	intensity)	for	the	ion	with	
+3	charge	reduced	from	+4	charge	precursor	isolation.	All	peaks	are	fitted	
into	Gaussian	curves.	(B)	Comparison	of	CCSs	of	the	same	ion	reduced	from	
different	charge	states.		 	
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Figure	3-6.	CCS	v.s.	mass	plot	for	all	detectable	ions	(including	precursor	and	
charge	reduced	ions).	All	points	are	fitted	in	three	individual	curves	with	
given	equations.	Proposed	stoichiometry	and	conformation	of	the	protamine	
dp20	complex	are	illustrated	in	cartoon.	Red	color	indicates	the	+4	ion	
precursor	that	is	not	distinguished	from	other	ions	at	m/z=3000.		 	
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CHAPTER	4	
	
MAPPING	MINIMAL	PROTEIN-BINDING	MOTIFS	USING	AN	ION-MOBILITY	TOP-
DOWN	MASS	SPECTROMETRY	APPROACH‡	
4.1	Introduction	Heparin	is	a	highly	sulfated	glycosaminoglycan	(GAG)	and	is	the	most	densely	negative	charged	natural-occurring	polymer.	It	is	known	for	its	roles	in	regulation	of	coagulant	 cascades.	 Heparin	 is	 a	 broad-spectrum	 anticoagulant	 reagent	 that	 has	been	used	in	many	circumstances	ranging	from	treatment	of	thrombosis	diseases	to	avoidance	 of	 blood	 clots	 during	 surgical	 operation	 and	 intravenous	 therapy1-3.	 In	addition,	 heparin-like	 GAG	 can	 bind	 to	 a	 large	 numbers	 of	 proteins	 through	 a	general	 polyanion-polycation	 interaction,	 exemplified	 by	 γ-interferon4	 and	 the	family	of	growth	factors	(GF).	 It	 is	well-established	that	growth	factors	can	trigger	numerous	 signals	 correlated	 to	 cell	proliferation	and	differentiation	when	binding	to	 growth	 factor	 receptors	 (GFR)5	 and	 the	 GF-GFR	 dependent	 signaling	 can	 be	facilitated	by	the	involvement	of	heparan	sulfates,	a	heparin-like	GAG	that	anchors	on	 the	 surface	 of	 cellular	 matrix.	 Although	 the	 majority	 of	 heparin-related	application	still	revolve	around	its	anticoagulant	effects,	the	use	of	heparin	to	build	nanomaterials	 (see	 section	 1.1.1.2)	 has	 become	 into	 an	 emerging	 technique	 in	medical	fields	such	as	tissue	engineer	and	therapeutic	protein	delivery6.	A	 prerequisite	 to	 understanding	 the	 mechanism	 of	 heparin/protein	interaction	 is	 to	 learn	 the	 structural	 detail	 in	 the	 “binding	 motif”	 where	 specific																																																									‡	This	entire	chapter	with	be	submitted	as	a	manuscript	for	publication	after	further	edition.	
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modification	patterns	(including	O-sulfation,	N-sulfation	and	N-acetylation)	within	a	limited	number	of	saccharide	units	are	required	for	interaction	with	client	proteins.	The	bottom-up	approach	to	identification	of	the	binding	motif	has	been	successfully	explored	 in	past	decades:	 a	 library	of	 oligosaccharide	with	 combinatory	 segments	was	applied	on	a	client	protein-conjugated	mobile	phase	for	separation	based	on	the	affinity.	 The	 pool	 containing	 the	 strongest	 affinity	 species	 was	 analyzed	 by	 mass	spectrometry	and	tandem	mass	spectrometry.7	However,	comprehensive	analysis	of	binding	 motif	 is	 extremely	 time-consuming	 as	 the	 heterogeneity	 in	 the	 samples	caused	 by	 the	 variety	 of	 chain	 lengths	 and	 modifications	 increases.	 For	 these	reasons,	our	knowledge	of	binding	motif	of	heparin	is	only	available	in	a	few	of	cases.	Herein	we	describe	an	alternative	top-down	approach	that	can	be	applied	on	the	complex	formed	by	protein	and	unfractionated	glycosaminoglycan	and	enable	a	rapid	 estimation	 on	number	 of	 saccharide	 and	 sulfate	 groups	within	 the	 required	minimal	 length	 of	 saccharide	 units	 without	 requiring	 complicated	 sample	preparation	 steps.	 Although	 the	 intact	 heparin	 is	 heterogeneous,	 the	 saccharide	units	and	sulfate	groups	that	actually	contribute	to	the	binding	are	always	limited	to	a	 small	 number	 of	 combinations.	 In	 addition,	 electrostatic	 interactions	 are	strengthened	when	samples	are	introduced	into	the	gas-phase,	where	the	shielding	effect	of	solvent	molecules	has	been	minimized.	We	hypothesize	that	heparin	chain	segments	that	are	not	bonded	to	the	protein	surface	will	fragment	very	readily	upon	collisional	 activation	 (via	 both	 glycosidic	 bond	 cleavage	 and	 sulfate	 “shedding”),	while	 the	 units	 involved	 in	 interaction	 with	 the	 protein	 will	 remain	 bound	 to	 it	(although	they	may	lose	“external”	sulfate	groups	not	stabilized	by	salt	bridges	with	
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the	protein	basic	groups)	(Figure	4-1).	However,	as	a	potential	pitfall,	unexpected	protein	 unfolding	 during	 collisional	 activation	 may	 damage	 the	 protein	conformation	 residing	 in	 the	 binding	 region	 and	 lead	 to	 a	 GAG	 releasing	 from	protein	 surface	 before	 being	 cleaved.	 To	 the	 date,	 the	 relation	 between	 unfolding	and	dissociation	of	protein-polyanion	complex	 in	response	to	collisional	activation	has	 not	 been	 explored.	 In	 this	 work,	 we	 will	 investigate	 the	 feasibility	 of	 this	approach	 on	 a	 well-studied	 system:	 acidic	 fibroblast	 growth	 factor	 (FGF)	 and	oligosaccharide	 heparin	 with	 fixed	 number	 of	 saccharide	 units.	 We	 are	 also	reporting	 the	relevant	behaviors	of	gaseous	 ion	of	protein-heparin	complex	under	collision	activation.	
4.2	Experimental	
4.2.1	Materials	and	Sample	Preparation	Recombinant	 human	 FGF-1	 protein	 (FGF)	 was	 purchased	 from	 GenScript.	Synthetic	 heparin	 mimetic	 pentasaccharide	 ArixtraTM	 (dp5)	 was	 a	 gift	 from	 Prof.	Robert	 Linhardt	 at	 Rensselaer	 Polytechnic	 Institute.	 Heterogeneous	 heparin	enzymatic	 degraded	 products	 with	 five	 disaccharide	 units	 (dp10)	 was	 purchased	from	Iduron	(UK).	Prior	to	mass	spectrometry	analysis,	FGF	was	incubated	with	dp5	or	dp10	in	buffer	containing	100mM	ammonium	acetate	at	pH	7.	All	proteins	for	CCS	calibration	were	purchased	from	Aldrich	Sigma	(St.	Louis,	MO).	
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4.2.2	Methods	The	 mixture	 of	 FGF	 and	 dp5	 or	 dp10	 was	 directly	 analyzed	 using	Waters	Synapt	G2Si	mass	spectrometer	equipped	with	nanospray	ion	source	(Milford,	MA).	Capillary	 voltage	 was	 set	 to	 1.2V.	 Sampling	 cone	 voltage	 was	 20V.	 Source	temperature	was	set	 to	30	°C.	 In	the	 ion-mobility	mode,	 traveling-wave	of	 the	IMS	cell	was	tuned	up	in	order	to	get	good	drift	time	peak	shape	and	position.	Trap	DC	voltage	was	kept	at	35V.	Gas-phase	 mass	 shedding	 and	 protein	 unfolding	 were	 monitored	 through	MS/MS	 experiment	 induced	 by	 collision	 with	 the	 argon	 gas.	 Ionic	 population	representing	 FGF	 alone	 or	 FGF-GAG	 complex	 was	 isolated	 using	 quadrupole.	Collision	 voltage	 was	 applied	 prior	 to	 ion-mobility	 separation	 and	 it	 was	 gained	stepwise	with	 10V	 interval	 until	 it	 reached	 120V.	 This	 voltage	 frame	was	 chosen	based	 on	 the	 property	 of	 ion	 and	 instrumentation	 condition.	 If	 applied	 collision	voltage	 goes	 beyond	 certain	 experimental	 frame,	 the	 ions	 with	 overwhelming	kinetic	 energy	 will	 be	 immediately	 scattered	 and	 unable	 to	 arrive	 to	 the	 TOF	analyzer	to	generate	any	meaningful	MS/MS	data.	Ion-mobility	mass	spectra	under	different	 energy	were	 acquired	 for	2	 to	5	minute	 for	 each	 to	make	 sure	 sufficient	signal-to-noise	ratio	can	be	achieved	for	analysis.	Acquired	data	were	interpreted	in	two	different	ways:	i)	collision-induced	unfolding	(CIU)	fingerprint	graph	was	used	to	describe	 the	unfolding	profile8	 of	 the	protein	 in	 the	 gas	phase	 against	different	activation	 energy	 in	 the	 presence	 or	 absence	 of	 GAG	 ligands;	2)	 collision-induced	dissociation	 (CID)	 was	 used	 for	 monitoring	 the	 mass	 loss	 of	 the	 protein-GAG	complex	 responding	 to	 the	 bond	 cleavage	 (including	 S-O	 and	 glycosidic	 bonds	 in	
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GAG	and	peptide	bonds	in	protein).	CIU/CID	followed	my	IMS/MS	measurement	has	been	applied	for	characterization	of	a	protein	binding	to	ligands	of	structural	variety	such	as	lipid9.	Collision	cross	section	(CCS)	of	an	 ion	was	acquired	based	on	the	drift	 time	value	at	the	apex	of	a	peak	in	the	ion-mobility	spectrum.	To	convert	drift	time	to	CCS	value,	 we	 took	 advantage	 of	 a	 calibration	 curve	 generated	 by	 acquiring	 the	 ion	mobility	 mass	 spectra	 of	 a	 series	 of	 native	 protein	 with	 established	 CCS	 values	including	 Cytochrome	 C,	 β-Lactoglobulin,	 Bovine	 serum	 albumin	 and	 Alcohol	dehydrogenase	 under	 equal	 instrument	 condition.	 Charge	 state	 and	mass	 of	 ions	were	considered	to	eliminate	the	effect	of	electric	field	on	drift	times	before	plotting	them	against	the	CCS	values.	The	detailed	steps	for	CCS	calibration	was	described	in	the	standard	protocol	for	protein	complex	CCS	calibration10.		
4.3	Results	and	Discussion	
4.3.1	 General	 Behaviors	 of	 Unbound	 FGF	 in	 response	 to	 the	 Gas-phase	
Collisional	Activation	The	 observed	 spectrum	 of	 FGF	 alone	 displayed	 three	 charge	 states	corresponding	to	a	mass	at	15,900	Da	(Figure	4-2A,	the	top	panel).	The	CCS	value	upon	the	major	charge	state	(+8)	 is	18.34nm2,	close	to	the	number	extracted	from	the	 crystal	 structure11,	 revealing	 that	 the	 protein	 has	 a	 similar	 conformation	presented	 in	 the	native	state.	We	 investigated	the	unfolding	profile	of	FGF	protein	by	stepwise	increasing	the	collision	voltage	in	the	trap,	where	selected	FGF	ions	can	be	 activated	 and	 all	 metastable	 populations	 can	 be	 captured	 by	 IM-MS.	 As	 the	
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collision	 energy	was	 increased,	 two	 other	major	 populations	 of	 FGF	 at	 +8	 charge	state	were	generated,	displaying	enlarged	CCS	values	compared	to	the	native	state.	These	 two	populations	 represent	 two	 intermediate	 conformations	during	 the	 gas-phase	 unfolding.	 The	 first	 intermediate	 has	 modest	 size	 expansion	 (14%	 CCS	enhancement)	 and	 it	 implies	 that	 the	 protein	 backbone	 is	 rearranged	 to	 an	extensive	 conformation	 in	 certain	 region(s);	 thus	 it	 is	 referred	 as	 a	 “partially	activated”	 state.	 The	 second	 intermediate	 has	 30%	 expansion	 compared	 to	 the	native	 CCS	 and	 it	 may	 represents	 a	 state	 where	 the	 protein	 globally	 loses	 its	structure	features,	thus	referred	as	a	“fully	unfolded”	state.	The	transition	between	different	 states	 can	 be	 monitored	 using	 the	 CIU	 fingerprint	 (Figure	 4-3A).	 For	instance,	 the	 +8	 charge	 state	 of	 FGF	 can	present	 its	 partially	 activated	 state	 at	 an	applied	energy	as	 low	as	32eV.	 In	this	chapter,	 the	applied	energy	 is	defined	to	be	the	product	of	applied	trap	collision	voltage	and	the	charge	state	of	the	selected	ion.	And	the	fully	unfolded	state	appeared	when	the	applied	energy	was	above	100eV.	It	became	 an	 exclusive	 population	when	 the	 applied	 energy	 reached	 220eV	 and	 the	populations	of	first	two	states	were	completely	converted	to	the	fully	unfolded	state.	The	measured	CCS	values	of	a	FGF	 in	other	charge	states	are	reasonable	as	well.	 FGF+7	 had	 smaller	 CCS	 value	 (17.5nm2)	 than	 FGF+8	 because	 of	 the	 reduced	Coulomb	 repulsion	 amongst	 positive	 charges.	 Relevant	 molecular	 dynamic	simulation	 studies	 have	 suggested	 that	 during	 collision-induced	 unfolding	 the	conformational	change	of	a	gaseous	protein	ion	is	associated	with	the	migration	of	charged	atoms	such	as	protons	and	salt	adducts12,13.	As	a	reasonable	hypothesis,	the	conformation	 of	 different	 intermediate	 states	 and	 the	 energy	 threshold	 to	 induce	
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the	transition	between	different	states	are	likely	to	be	affected	by	the	actual	surface	charge.	Indeed,	given	our	results	shown	in	the	CIU	fingerprint	(Figure	4-3,	A	vs.	B),	both	 of	 the	 two	 intermediate	 states	 of	 FGF	 still	 existed	 in	 the	 lower	 charge	 state	FGF+7;	 and	 they	 had	 relatively	 smaller	 CCS	 values	 compared	 to	 the	 higher	 charge	state	 FGF+8.	We	 also	 observed	 that	 FGF+7	was	more	 resistant	 to	 collision-induced	activation	 than	 FGF+8.	 For	 FGF+7,	 the	 energies	 triggering	 the	 first	 transition	 (from	native	 state	 to	 the	 partially	 activated	 state)	 and	 the	 second	 (from	 the	 partially	activated	 state	 to	 the	 fully	 unfolded	 state)	were	 definitely	 improved	 compared	 to	those	for	FGF+8,	because	we	can	clearly	see	that	the	partially	activated	state	of	FGF+7	did	not	 appear	until	 200eV	 (vs.	 32eV	 for	 FGF+8)	 and	 it	 remained	 as	 the	dominant	population	across	the	entire	energy	range	in	our	experimental	frame	(up	to	770eV).	In	 addition,	 the	 population	 of	 the	 fully	 unfolded	 state	 remained	 in	 modest	abundance	(<10%	of	the	total	 ionic	 intensity).	We	anticipated	that	the	energy	that	was	 capable	 to	 induce	majority	 of	 fully	 unfolded	 FGF+7	is	 out	 of	 the	 experimental	frame.	Collisional	activation	also	caused	ubiquitous	protein	fragmentation	for	both	+7	and	+8	charge	states	in	company	with	protein	unfolding.	It	should	be	noted	that	even	 in	 the	 case	 of	 +8	 ion,	 where	 protein	 unfolding	 is	 easier	 and	 protein	fragmentation	 is	more	 dramatic,	 a	 population	 of	 parent	 ions	 survives	 and	 can	 be	distinguished	 from	 the	 ionic	 signals	 of	 fragmentation	 in	 the	 ion-mobility	 mass	spectra,	as	shown	in	Figure	4-S2A.	
	 77	
4.3.2	Collision-induced	Unfolding	and	Dissociation	of	the	Complex	Formed	by	
FGF	and	Homogeneous	Pentasaccharide	The	rationale	of	the	top-down	approach	for	identifying	FGF-binding	heparin	segments	 was	 initially	 tested	 using	 a	 synthetic	 pentasaccharide	 (dp5),	 which	contains	a	homogeneous	structure	and	modification	pattern.	Although	this	molecule	was	 originally	 designed	 as	 a	 mimetic	 of	 a	 heparin	 segment	 for	 antithrombin	modulation,	 it	 can	 bind	 to	 FGF	 as	 well	 because	 it	 consists	 in	 critical	 structural	features	 related	 to	 the	 FGF-binding	 affinity14	 (highlighted	 in	 Figure	 4-2B).	 The	interaction	 between	 dp5	 and	 FGF	 can	 be	 directly	 probed	 using	 native	 mass	spectrometry	(Figure	4-2A).	The	spectrum	of	FGF	in	the	presence	of	dp5	shows	that	FGF	 and	 dp5	 can	 only	 form	 1:1	 complex	 (FGFdp5)	 and	 there	 is	 no	 evidence	suggesting	other	stoichiometries	are	present.	The	CCS	for	the	complex	based	on	the	+7	charge	state	is	17.80	nm2	and	this	value	is	very	close	to	that	of	unbound	FGF	at	17.50	nm2,	suggesting	that	this	minute	CCS	increment	(+1.7%)	is	contributed	by	the	size	of	dp5	itself	when	it	presents	on	the	protein	surface	and	does	not	induce	major	conformational	change	of	the	protein.	Similar	 to	 unbound	 FGF,	 when	 (FGFdp5)+7	 was	 treated	 with	 collisional	activation	both	protein	unfolding	 and	 fragmentation	were	observed.	However,	we	also	observed	 that	an	 intense	peak	 in	 the	product	 ion	 spectra	gradually	 shifted	 to	the	 lower	 m/z	 as	 the	 collisional	 energy	 increases,	 starting	 from	 the	 m/z	 value	corresponding	 to	 precursor	 (FGFdp5)+7,	 and	 finally	 stopped	 by	 the	 m/z	 value	corresponding	 to	 unbound	 FGF+7.	 This	 peak	 represents	 the	 FGFGAG	 complex	whose	saccharide	components	are	stripped	from	the	complex	successively	and	the	protein	component	still	remains	intact	during	this	process.	To	examine	how	binding	
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to	 dp5	 or	 GAG	 fragments	 affects	 the	 protein	 unfolding	 pathway,	we	 focused	 on	 a	population	 of	 FGFGAG	 (without	 taking	 any	 unbound	 FGF	 population)	 in	 each	spectrum	for	extraction	of	CIU	fingerprint.	It	clearly	shows	that	the	energies	for	both	transitions	are	lower	compared	to	those	of	unbound	FGF+7	(Figure	4-3,	B	vs.	C).	We	can	conclude	that	interaction	with	dp5	does	not	change	the	number	of	intermediate	states	or	significantly	affect	their	conformations	but	it	inhibits	protein	unfolding	by	stabilizing	individual	states.	The	 correlation	 between	 the	 protein	 conformation	 and	 the	mass	 loss	were	studied	based	on	average	mass	spectra	scanned	within	ion-mobility	arrival	time	of	each	state	individually.	For	the	native	state	(Figure	4-4A,	grey	trace),	the	spectrum	under	mild	activation	(350eV)	displays	a	group	of	equally	spaced	peaks	(∆m=22Da)	corresponding	to	the	mass	of	FGFdp5	plus	various	number	of	sodium	adducts.	The	sodium	ions	are	extensively	attached	onto	dp5	molecule,	observed	in	the	spectrum	of	dp5	alone	(Figure	4-S1A).	When	the	applied	energy	was	increased	to	490eV,	two	more	groups	of	peaks	with	79Da	less	than	the	original	group	appear,	indicating	the	loss	of	sulfate	groups.	For	the	native	states,	we	did	not	observe	other	reasons	that	caused	 mass	 decreases	 rather	 than	 sulfate	 shedding.	 The	 mass	 spectra	 of	 the	complex	 in	 the	 partially	 activated	 state	 (Figure	 4-4A,	 blue	 trace)	 are	 identical	 to	those	in	the	native	state	against	the	applied	energy	under	560eV.	When	the	applied	energy	went	above	560eV,	 the	native	population	was	completely	 converted	 to	 the	partially	activated	state;	meanwhile	some	 ionic	signals	appeared	corresponding	 to	the	 gradual	 mass	 decrease	 in	 a	 larger	 interval	 than	 the	 one	 caused	 by	 sulfate	shedding.	 When	 the	 applied	 voltage	 is	 above	 700eV,	 two	 distinct	 populations	 of	
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fragment	 ions	 became	 apparent,	 one	 representing	 FGF	 with	 pentasaccharide	residues	 containing	 two	 sulfate	 groups	 (m/z	 ~	 2430)	 and	 the	 other	 with	trisaccharide	residues	(m/z	~	2390).	It	suggests	that	the	unbound	saccharide	units	can	 be	 removed	 from	 the	 FGF	 surface	 in	 the	 partially	 activated	 state	 through	glycosidic	 bond	 cleavage	 (Figure	 4-4B,	 blue	 trace).	 In	 the	 fully	 unfolded	 state	(Figure	4-4B,	red	trace),	GAG	fragmentation	occurred	dramatically	and	an	unbound	FGF	peak	(m/z	=	2283)	became	dominant.	These	results	demonstrate	that	as	long	as	the	complex	stays	native	or	partially	activated,	the	heparin-binding	domain	of	FGF	is	intact	 and	 the	 specific	 interactions	 including	 H-bonds	 formed	 between	 protein	residues	and	the	sulfate	or	carboxyl	groups	on	GAG	are	normally	maintained.	In	the	fully	 unfolded	 conformation,	 essential	 protein	 structural	 features	 for	accommodation	of	GAG	ligand	are	lost	and	therefore	the	remaining	saccharide	units	can	 be	 rejected	 immediately.	 These	 results	 also	 suggest	 that	 “non-essential	segment”	 in	 the	native	state	of	 the	gaseous	 ion	may	be	collapsed	onto	 the	protein	surface	 via	 long-distance	 electrostatic	 forces.	 These	 non-specific	 interactions	 play	important	roles	in	stabilize	the	native	conformation.	In	the	partially	activated	state,	the	 structural	 features	 related	 to	 the	 non-specific	 interaction	 are	 disrupted	 and	therefore	 the	 non-essential	 segment	 happens	 to	 detach	 from	 the	 protein	 surface	after	being	cleavage.	The	m/z	values	of	the	dominant	peaks	are	plotted	against	applied	energy	for	all	 three	states	(Figure	 4-5).	As	a	negative	control,	unbound	FGF+8	does	not	show	any	 collision-dependent	mass	 decrease	 (Figure	 4-5).	 The	 value	 of	 (FGFdp5)+7	 in	the	 partially	 activated	 state	 (blue	 open	 dots)	 keeps	 decreasing	 and	 then	 remains	
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unchanged	 at	 two	values,	 corresponding	 to	 FGF	plus	dp5	with	 two	 sulfate	 groups	(5,2,0)	and	FGF	plus	dp3	(two	uronic	acids	and	one	glucosamine)	with	two	sulfate	groups	(3,2,0),	respectively.	This	latter	represents	the	last	GAG	components	that	can	reside	in	FGF	that	is	not	fully	unfolded	and	it	is	assumed	to	be	the	minimal	segment	to	 achieve	 specific	 binding.	 Indeed,	 this	 number	 is	 very	 close	 to	 the	 predicted	binding	 segment	 (3,3,0)	based	on	previously	 confirmed	 trisaccharide	motif	 that	 is	directly	involved	in	the	interaction	with	FGF	(Figure	4-1A).	
4.3.3	Probing	interaction	between	FGF	and	heterogeneous	decasaccharide	We	 hypothesize	 that	 this	 established	 approach	 for	 identifying	 the	 binding	motif	 of	 heparin	 can	 generate	 a	 constant	 result	 no	 matter	 the	 heparinoid	 chain	length	and	heterogeneity.	FGF	was	incubated	with	decasacharide	(dp10)	containing	diverse	 sulfation	pattern,	which	was	 isolated	 from	 the	native	heparin	degradation	products	using	size-exclusion	chromatography,	and	was	analyzed	using	native	mass	spectrometry.	The	stoichiometry	of	the	complex	formed	by	FGF	and	dp10	cannot	be	determined	upon	 the	acquired	mass	 spectrum	alone	because	 the	peaks	are	 rather	broad	 and	 partially	 convoluted	 due	 to	 the	 intrinsic	 mass	 heterogeneity	 of	 dp10	(Figure	 4-6A	 and	 Figure	 4-S1B).	 Ion-mobility	 can	 considerably	 enhance	 the	confidence	 of	 charge	 state	 assignment	 for	 the	 reasons	 that	 (1)	 adjacent	 ions	with	different	charge	can	be	fully	resolved	based	on	their	drift	time	and	(2)	the	CCSs	for	all	tentative	charge	states	of	the	same	specie	are	supposed	to	be	constant.	In	order	to	 separate	 ions	 that	 have	 different	 charges	 but	 still	 overlap,	 for	 instance	 the	population	at	m/z	2700,	a	mild	collisional	voltage	(50V)	was	applied	to	all	ions	and	
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it	 was	 expected	 to	make	 the	 overlapped	 ions	 distinguishable	 through	 differential	protein	 activation	 because	 the	 ion	 with	 higher	 charge	 actually	 bear	 higher	collisional	energy.	As	a	result,	one	series	of	ions,	which	are	supposed	to	have	higher	charge,	 readily	 shift	 into	 the	 region	 of	 the	 field	 with	 higher	 drift	 times.	 They	represent	 a	 ternary	 complex	with	 two	 FGF	molecules	 bridged	 by	 one	 dp10	 chain	(FGF2dp10),	 which	 is	 consistent	 with	 previous	 observations15,16,	 while	 the	remaining	 series	 of	 ions	 that	 are	 relatively	 inert	 to	 activation	 represent	 the	 1:1	complex	 (FGFdp10)(Figure	 4-6B).	 The	 coexistence	 of	 two	 stoichiometries	 are	verified	by	a	post-IM	CID	for	the	ionic	populations	at	m/z=2700	(Figure	4-6C).	The	1:1	complex	FGFdp10	at	+7	and	+8	were	individually	isolated	and	were	followed	with	stepwise	 increased	collisional	voltage.	The	complex	shows	the	same	behaviors	as	FGFdp5	(Figure	 4-S2	 and	Figure	 4-S3).	Briefly,	GAG	 fragmentation	occurred	 with	 protein	 unfolding.	 In	 the	 presence	 of	 dp10,	 protein	 in	 the	 lower	charge	state	had	the	smallest	transition	energy	between	different	folding	states	and	the	mass	loss	of	the	complex	in	the	partially	activated	state	was	much	more	gentle	compared	 to	 that	 in	 the	 fully	 unfolded	 state.	 Based	 on	 the	 mass	 loss	 profile	 of	(FGFdp10)+7	 in	 the	 partially	 activated	 state,	 the	 energy	 threshold	 for	 removing	non-specifically	attached	saccharide	units	is	about	95V	(665eV),	similar	to	the	value	in	FGFdp5	complex.	However,	 the	mass	of	GAG	remaining	 in	 the	protein	complex	falls	 in	 the	 range	 corresponding	 to	 the	 tetrasaccharide	 (Figure	 4-S4).	 We	 also	observed	a	peak	at	m/z	2664,	representing	the	GAG-free	FGF	with	+6	charge,	when	collisional	voltage	was	above	90V	(630eV)	and	this	charge-reduced	product	ion	only	had	one	major	population	with	a	CCS	value	as	small	as	the	native	protein.	Therefore,	
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it	 is	very	 intriguing	that	the	protein	does	not	need	to	be	fully	unfolded	in	order	to	release	 the	 remaining	 GAG-FGF	 interactions	 but	 it	 can	 be	 refolded	 to	 an	 even	smaller	 size	 only	 if	 one	 charge	 on	 the	 protein	 is	 stripped	 off	 by	 the	 leaving	 GAG.	However,	 this	 pathway	 is	 only	 found	 in	 (FGFdp10)+7	 and	 the	 reason	 is	 still	 not	clear.	 We	also	investigated	the	FGF2dp10	ions	under	collisional	voltage.	Contrary	to	 our	 expectation,	 prior	 to	 the	 energy	 reaching	 the	 threshold	 to	 trigger	 CID	 of	bound	 dp10,	 FGF2dp10	 follows	 a	 typical	 pathway	 of	 collision-induced	 protein-protein	 complex	 dissociation	 with	 asymmetric	 charge	 partitioning17:	 one	 protein	monomer	 is	 rapidly	 unfolded	 and	 released	 from	 remaining	 binary	 complex.	Therefore,	 this	gas-phase	approach	may	not	be	used	 for	estimation	of	 the	binding	motif	 in	 a	 heparinoid-bridged	 ternary	 complex	 as	 long	 as	 the	 proteins	 directly	contact	to	each	other.	
4.4	Conclusions	This	 approach	 is	 a	 potential	 tool	 for	 estimating	 the	 number	 of	 sulfate	 and	saccharide	units	within	 the	binding	motif	of	GAG.	As	suggested	 from	our	FGF•dp5	data,	FGF	binding	will	afford	the	heparinoid	segment	protection	from	the	collision-induced	 saccharide	 degradation	 locally,	 while	 the	 segments	 not	 involved	 in	 the	interaction	 will	 be	 removed.	 However,	 the	 performance	 of	 this	 approach	 really	depends	 on	 the	 energy	 threshold	 for	 different	 effects	 induced	 by	 collision.	 In	general,	 shorter	heparinoid	 chains	 required	 lower	energy	 to	 achieve	 the	 last	 step,	where	 all	 unnecessary	 components	 of	 GAG	 are	 removed.	 A	 lower	 charge	 state	
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should	 be	 chosen	 for	 CID	 to	 avoid	 malice	 protein	 unfolding;	 otherwise	 no	meaningful	fragmentation	data	can	be	generated.	The	 protein	 unfolding	 intermediates	 can	 be	 easily	 monitored	 using	 IMS.	However	this	is	not	a	strict	approach	that	can	reveal	details	of	the	protein	structure.	Detailed	 simulations	 must	 be	 carried	 on	 in	 future,	 so	 we	 will	 know	 the	 location	where	the	unfolding	happens.	Nevertheless,	the	approach	described	in	this	chapter	allows	us	to	monitor	the	status	of	the	ions	manipulated	in	the	gas	phase.		 	
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Figure	4-1.	Schematic	of	a	gas-phase	“top-down”	approach	to	identify	the	
protein-binding	of	motif	in	unfractionated	heparin		 	
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Figure	4-2.	(A)	Native	MS	of	FGF	alone	and	in	the	presence	of	synthetic	dp5.	(2)	
The	GAG	components	involved	in	the	FGF-binding	(highlighted	in	purple)	are	
predicted	based	on	the	known	binding	motif	identified	in	standard	dp4	
(within	the	brackets)		 	
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Figure	4-3.	CIU	fingerprint	graphs	of	(A)	FGF+8,	(B)	FGF+7	and	(C)	FGF•dp5+7			 	
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Figure	4-4.	Fragmentation	of	FGF•dp5+7	induced	in	different	unfolding	states	
(A)	below	490	eV	(70V)	and	(B)	above	630	eV	(90V).		 	
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Figure	4-5.	Plots	of	m/z	value	of	survived	FGF•GAG	complex	or	FGF	ions	versus	
applied	activation	energy.		 	
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Figure	4-6.	Characterization	of	FGF/dp10	complexes	using	IMS-MS:	(A)	mass	
spectrum	of	FGF/dp10	mixture;	(B)	distinguish	of	overlapping	populations	
using	pre-IM	activation	followed	IMS-MS;	(C)	verification	of	the	identities	of	
two	populations	with	the	same	m/z	using	post-IM	CID.			 	
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Figure	4-S1.	Mass	spectra	of	(A)	synthetic	dp5	and	(B)	dp10	acquired	in	the	
negative	mode.		 	
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Figure	4-S2.	IMS-MS	of	FGF	alone	and	in	presence	of	dp10	under	different	
collisional	voltage.	Critical	changes	regarding	the	mass	and	conformation	are	
labeled	on	the	graphs.							
	
Figure	4-S3.	CIU	fingerprint	for	FGF•dp10	at	+8	and	+7	charge	states		 	
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Figure	4-S4.	Monitoring	the	mass	loss	of	FGF•dp10+7	at	different	collisional	
voltage.	The	last	survived	complex	is	probed	and	compared	with	the	one	
deduced	from	FGF•dp5+7.	
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CHAPTER	5	
	
DEVELOPING	A	NOVEL	PLATFORM	BASED	ON	ENZYMATIC	DEGRADATION	AND	
SIZE-EXCLUSION	CHROMATOGRAPHY-MASS	SPECTROMETRY	FOR	
IDENTIFYING	PROTEIN-BINDING	MOTIFS	IN	HEPARIN-LIKE	
GLYCOSAMINOGLYCANS§	
5.1	Introduction	Heparin-like	 glycosaminoglycan	 play	 crucial	 roles	 in	 regulation	 of	 diverse	functions.	However	deciphering	the	mechanisms	of	heparin-mediated	regulation	is	challenging	due	to	the	tremendous	structural	variety	of	heparin	chains,	defined	by	modifications	 including	 O-sulfation,	 N-sulfation	 and	 N-deacetylation	 within	 a	disaccharide	 repetitive	 unit.	 The	 modification	 is	 controlled	 enzymatically	 by	mechanisms	 that	 are	 still	 unclear,	 which	 leads	 to	 combinatorial	 modification	patterns	 presented	 in	 naturally-occurring	 heparin-like	 GAG	 samples.	 In	 the	 last	chapter,	we	described	a	mass	spectrometry-based	approach	to	identify	the	minimal	binding	motif	 of	 heparin	 (defined	 by	 the	 number	 of	 sulfate	 group	 and	 saccharide	unit	 within	 the	 interface),	 which	 utilizes	 a	 “top-down”	 idea	 to	 chop	 off	 the	unessential	components	(including	GAG	chains	and	the	sulfate	groups	that	are	not	involved	in	the	interaction)	from	a	protein-heparin	complex.	Mass	measurement	of	the	surviving	complex	indicates	the	minimal	binder.	However,	as	we	have	shown	in	the	 last	 chapter,	 the	 gas-phase	 collision-induced	 fragmentation	 of	 GAG	 in	 a	
																																																								§	The	data	reported	in	this	chapter	will	be	in	a	manuscript	for	publication.	
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meaningful	way	is	limited	to	a	simple	system	consisting	of	PTM-free	protein	and	the	heparin	chain	shorter	than	10	saccharide	units.		In	 this	 chapter,	 we	 introduce	 an	 alternative	 procedure	 in	 which	 the	degradation	 of	 GAG	 component	 is	 induced	 in	 a	 manner	 of	 enzymatic	 digestion.	Heparinase-based	heparin	degradation	used	to	have	a	routine	application	to	create	low-molecular-weight	heparin1-3.	We	expected	that	heparinase	would	degrade	every	disaccharide	 unit	 along	 the	 GAG	 chain	 gradually	 except	 in	 the	 region	 where	 the	client	protein	is	interacting.	In	order	to	achieve	this	goal	in	an	unbiased	fashion,	the	family	 II	of	heparinase	 is	chosen	 from	all	 candidates	 for	 the	 following	advantages:	(1)	 it	 has	 the	 least	 preference	 to	 the	 cleavage	 site	 and	 can	 digest	 along	 the	polysaccharide	chain	in	both	sulfate-rich	domain	and	neutral	domain;	(2)	only	two	saccharide	units	one	each	side	of	the	scissile	bond	(P1	P2	|	P1’	P2’)	of	GAG	chain	are	required	 for	 initiating	 the	 enzymatic	 recognition4,5	 so	 that	 it	 can	 access	 the	saccharide	 adjacent	 to	 the	 region	 protected	 by	 client	 protein	 and	 “clean	 out”	 the	unbound	 components	 thoroughly.	 In	 pursuit	 of	 high	 performance	 of	 analysis,	 we	developed	 an	 online	 size-exclusion	 chromatography	 (SEC)	 native	 mass	spectrometry	(MS)	platform,	which	embraces	the	benefits	from	the	both	techniques	(Figure	 5-1A).	 It	 allows	 the	 surviving	 protein	 complex	 to	 be	 isolated	 from	 the	degraded	GAG	products	and	to	subject	to	a	real-time	ion	detection	by	MS.	Native	MS	has	 been	 successfully	 used	 for	 sorting	 the	 binders	 from	 a	 combinatorial	oligosaccharide	 complex	 upon	 the	 affinity	 to	 a	 protein6.	 Based	 on	 our	 previous	experience,	 the	performance	of	native	MS	 including	 resolution	and	dynamic	 range	for	detection	in	a	heterogeneous	sample	can	be	significantly	improved	vis-à-vis	the	
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incorporation	 of	 online	 chromatography7.	 And	 the	 elution	 profile	 for	 individual	species	 can	 be	 extracted	 and	 it	 allows	us	 to	monitor	 the	 dynamic	 impact	 on	 each	other8.	In	addition,	although	the	digestion	is	carried	on	in	the	solution	phase,	we	can	still	take	advantage	of	the	gas-phase	chemistry	to	get	rid	of	the	unessential	sulfate	in	the	protein-interacting	domain,	which	cannot	be	removed	in	the	step	of	heparinase	treatment.	In	 this	work,	we	 test	 this	 approach	 for	 the	 binding	motif	 for	 antithrombin,	which	 has	 been	 well	 established	 (Figure	 5-1B)	 in	 previous	 studies9,10,	 in	 the	complex	with	heparin	oligosaccharide	with	20	units.	
5.2	Experimental	Antithrombin-III	 (AT)	 dominantly	 consisting	 of	 the	 α-form	 (with	 four	glycosylation	 chains)	 was	 purchased	 from	 Haematologic	 Technologies	 (Essex	Junction,	 VT).	 Heparin	 oligosaccharide	 dp20	was	 purchased	 from	 Iduron	 (UK).	 In	order	to	form	a	strong	complex,	AT	and	dp20	were	incubated	in	1:5	molar	ratio	at	room	temperature	for	30	min	in	the	solution	containing	30mM	ammonium	acetate	at	pH	7.	Heparinase	 II	was	added	 into	 the	mixture	 to	a	 final	concentration	8	u/ml	and	 incubated	 for	 another	 30min	 at	 35	 degree.	 The	 sample	 was	 immediately	transferred	in	to	a	sample	vial	and	ready	for	SEC-MS	analysis.	The	platform	of	SEC-native	MS	is	shown	in	Figure	5-2A.	Chromatography	is	carried	 on	 in	Agilent	 1100	 equipped	with	 autosampling	 system.	The	 flow	 rate	 for	SEC	(TSK	G3000)	separation	is	set	to	0.3	ml/min.	A	fluid	splitter	was	employed	to	reduce	 the	 flow	 prior	 to	 injection	 to	 the	 source	 of	 Bruker	 SolariX	 FT-ICR	 mass	
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spectrometer	(Billerica,	MA).	In	source	CID	voltage	was	set	to	60V.	Sample	injection	and	 data	 acquisition	 was	 triggered	 from	 computer	 using	 Hystar	 software.	 GAG-ligand	 can	 be	 dissociated	 from	 the	 protein	 complex	 by	 mixing	 with	 methanol	solution	containing	12%	acidic	acid.	The	solution	was	pumped	into	a	fluid	mixture	by	another	HPLC	at	the	same	flow	rate	(0.3	ml/min),	where	the	SEC	fluid	was	mixed	with	 the	 denaturing	 solution	 allowing	 the	 protein	 complex	 to	 be	 denatured	 and	release	 the	 GAG	 ligand.	 The	 released	 GAG	 was	 then	 subjected	 to	 the	 mass	spectrometer	for	an	accurate	mass	measurement	(Figure	5-2B).	Online	LC-MS	data	was	processed	using	DataAnalysis	software.	
5.3	Results	and	Discussion	
5.3.1	SEC-native	MS	analysis	of	the	heparinase-digested	products	of	AT•dp20	
complex	The	digestion	mixture	passed	through	SEC	column	with	two	major	retention	times	displayed	on	the	UV	trace	(Figure	5-3A,	grey	trace).	The	early	peak	(eluted	at	19-22min)	represents	the	protein-GAG	protein	mixture	and	the	late	peak	(eluted	at	28-30min)	 represents	 the	 pieces	 of	 disaccharide	 degraded	 from	 the	 intact	 GAG	chain.	 There	 are	 some	 early-eluted	 species	 with	 very	 low	 UV	 absorbance	 (25-28min)	 corresponding	 to	 the	 GAG	 components	 with	 longer	 polysaccharide	 chain	produced	by	incomplete	digestion.	The	Base	Peak	Chromatogram	(BPC)	reflects	the	time	when	ionic	signal	was	actually	detected	by	MS	and	it	shows	an	obvious	delay	(~2	 min)	 compared	 to	 the	 UV	 profile.	 Upon	 the	 BPC	 profile,	 the	 average	 mass	spectra	within	three	continuous	time	windows	in	the	early	major	peak	are	shown	in	
Figure	5-3B.	We	clearly	saw	that	during	such	a	short	period	less	than	1.5	min,	three	
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species	 were	 eluted	 one	 after	 another	 and	 successfully	 detected	 by	MS.	 The	 first	spectrum	represents	AT•dp20,	 and	perhaps	other	unresolved	 species.	The	 second	spectrum	displays	many	peaks	corresponding	 to	 the	complexes	 formed	by	AT	and	GAG	with	different	mass	ranging	 from	dp6	to	dp10.	They	were	produced	from	the	partial	digestion	of	GAG	in	the	presence	of	AT.	The	third	spectrum	is	only	comprised	of	the	GAG-free	AT.	We	did	not	observe	any	AT-involved	complex	that	contains	less	than	6	saccharide	units	during	any	period	of	elution.	The	order	of	the	peak	elution	also	agrees	with	chain	length	of	the	GAG	binding	to	the	protein.	Based	 on	 the	 spectrum	 with	 +16	 ions	 of	 AT	 in	 complex	 with	 short	 chain	oligosaccharide	 (i.e.	 AT•dp6+16,	 AT•dp8+16,	 AT•dp10+16),	 only	 one	 sharp	 and	abundant	 peak	 was	 observed	 for	 each	 complex	 (see	 Figure	 5-3C	 for	 a	 zoom-in	view),	corresponding	to	(6,6,1),	(8,9,1)	and	(10,12,1)	respectively.	(In	the	standard	nomenclature	 system	 of	 GAG,	 (X,Y,Z)	 represents	 the	 structure	 in	 terms	 of	 the	number	 of	 saccharide	 (X),	 the	 number	 of	 sulfate	 groups	 (Y)	 and	 the	 number	 of	acetylation	 groups	 (Z).)	 These	 numbers	 indicate	 the	 specific	modification	 pattern	that	 plays	 the	 most	 important	 roles	 in	 AT-binding.	 Mass	 accuracy	 of	 our	measurement	 is	shown	in	Table	5-1.	The	binders	with	other	patterns	either	 leave	from	the	protein	in	the	early	stage	or	have	the	unessential	sulfate	groups	to	be	shed	in	 the	gas-phase	during	 in-source	CID.	The	elution	profiles	extracted	 for	 the	 three	peaks	 indicate	 that	 AT•(6,6,1)	 is	 the	 most	 abundant	 complex	 that	 survived	 from	heparinase	treatment	and	in-source	purging	(Figure	5-3D).	It	is	well	known	that	AT	can	specifically	interact	with	a	piece	of	GAG	containing	a	pentamer	(5,6,1).	Although	additional	sulfate	groups	and	saccharide	units	may	also	enhance	the	binding	affinity,	
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the	 six	 sulfates	 presented	 in	 Figure	 5-1B	 are	 most	 important	 and	 represent	 the	minimal	requirement	to	trigger	strong	and	specific	interaction,	which	has	also	been	demonstrated	 in	 a	 crystal	 structure.	 Our	 results	 are	 highly	 consistent	 with	 what	have	been	identified	previously	in	terms	of	the	numeric	modification	pattern.	In	our	harsh	condition,	all	unessential	sulfate	groups	are	shed,	even	some	of	those	that	may	contribute	to	the	specific	or	non-specific	interactions.	As	a	conclusion,	the	binder	for	a	protein	can	be	determined	 in	a	one-step	measurement	with	high	mass	accuracy;	while	 the	 traditional	 ways	 to	 identify	 the	 binder	 of	 strong	 affinity	 is	 very	 time-consuming.		
5.3.2	Identification	of	the	GAG	ligand	through	online	protein	denaturation	Measuring	the	mass	of	intact	complex	using	native	MS	is	promising	however	the	lack	of	the	isotopic	peaks	for	a	highly	charged	ion	of	protein-GAG	complex	(e.g.	AT•(6,6,1)+16	 in	 Figure	 3C)	 probably	 leads	 to	 inaccurate	mass	measurements.	 For	this	reason,	we	designed	an	experimental	setup	(illustrated	in	Figure	5-2B)	that	is	able	 to	 dissociate	 the	 remaining	minimal	 binder	 from	 the	 protein	 complex	 via	 an	online	 denaturing.	 It	 allows	 the	 binder	 itself	 to	 be	measured	 using	 FT-MS,	 which	gives	more	accurate	results	compared	to	the	measurement	of	non-covalent	complex	using	native	MS.	First,	we	test	whether	a	protein	can	undergo	unfolding	by	mixing	with	the	denaturing	solution	after	the	native	protein	is	from	SEC	column.	The	mass	spectra	for	the	SEC	peaks	of	BSA	are	shown	in	Figure	5-S1,	where	the	low	m/z	of	charge	envelops	of	both	monomeric	and	dimeric	BSA	apparently	indicates	that	the	protein	has	an	unfolded	conformation	during	electrospray.	Then	we	tested	whether	
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the	unfolded	AT	can	 release	a	 small	GAG	 ligand,	ArixtraTm	 (5,8,0).	 It	 is	 a	 synthetic	mimic	of	 the	pentameric	binder	with	 the	same	modification	pattern,	except	 for	an	additional	 sulfate	group	 replacing	 the	acetylation	group	 in	 the	naturally-occurring	binder	(5,6,1)	or	(5,7,1).	The	UV	trace	of	 the	chromatogram	is	 identical	 to	 the	one	without	 mixing	 with	 denaturant	 because	 the	 denaturation	 step	 occurs	 after	 UV	detection.	 Only	 one	 peak	 is	 visible	 in	 the	 chromatogram,	 characterized	 by	 the	AT•Arixtra	complex	according	to	its	retention	time	(Figure	5-4A,	grey	trace).	The	identity	of	this	peak	is	also	verified	based	on	the	native	mass	spectra	(Figure	5-4B,	
green	trace),	in	which	no	free	AT	is	observed.	In	contrast,	no	AT•Arixtra	is	survived	in	denatured	MS	(Figure	5-4B,	blue	trace),	suggesting	that	the	ligand	is	dissociated	from	 the	 complex.	During	 the	 sample	preparation,	Arixtra	was	 added	 in	 excess	 to	the	sample	so	there	is	another	peak	eluted	at	~25	min	corresponding	to	the	excess	Arixtra,	 which	 cannot	 be	 seen	 in	 UV	 trace	 because	 Arixtra	 does	 not	 have	 UV	absorption.	 The	 mass	 spectrum	 of	 Arixtra	 was	 acquired	 in	 the	 negative	 mode	 in	order	 to	 reach	 the	 best	 sensitivity,	 in	 which	 the	 isotopic	 peaks	 of	 Arixtra	 can	 be	clearly	 observed	 (Figure	 5-4B,	 orange	 trace).	 Extracted	 ion	 chromatogram	 for	Arixtra	 display	 two	 peaks	 (Figure	 5-4A,	 orange	 trace),	 one	 (at	 ~25	 min)	representing	the	excess	fraction	not	involved	in	the	interaction	with	AT	and	another	(at	~20	min)	representing	the	fraction	in	AT•Arixtra	complex	as	an	attached	ligand.	Therefore,	we	can	probe	the	identity	of	GAG	ligands	within	the	same	time	window	when	the	protein	complex	is	eluted	using	this	online	denaturing	approach.	
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5.4	Conclusions	The	existence	of	unbound	AT	 suggests	 that	 there	 is	 a	 competition	between	AT	and	heparinase	in	terms	of	the	binding	affinity	to	heparin	chains.	Generally,	for	an	enzyme,	a	higher	substrate	turnover	rate	will	make	the	affinity	for	the	substrate	weaker	(KM),	therefore	heparinase	digestion	should	be	carried	out	under	conditions	where	 the	 enzyme	has	 highest	 turnover	 rate,	 in	 order	 to	 avoid	 stripping	 the	GAG	chain	off	from	the	surface	of	AT.	We	described	in	the	previous	chapter,	non-specific	electrostatic	interaction	is	remarkable	in	the	gas-phase	and	likely	to	force	the	entire	heparin	chain	to	collapse	on	the	surface	of	the	protein,	which	prevent	the	saccharide	with	weak	interaction	from	being	removed.	In	the	solution	phase,	this	accessibility	issue	has	been	circumstance.	Our	data	strongly	suggest	that	the	regions	of	dp20	that	does	 not	 contribute	 to	 the	 strong	 interaction	 can	 be	 accessed	 by	 heparinase	 for	cleavage.			 	
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Figure	5-1	(A)	Workflow	of	approach	based	on	enzymatic	degradation	to	
identify	the	minimal	protein-binding	motif	for	heparin-like	GAG.	(B)	
Previously	identified	minimal	binding	segment	for	antithrombin-III;	the	
critical		 	
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Figure	5-2.	Schematics	of	(A)	SEC-native	MS	and	(B)	SEC-denatured	MS.		 	
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Figure	5-3.	SEC-MS	of	heparinase-treated	AT-dp20	complex	(A)	SEC	profile	of	
heparinase-treated	AT-dp20	complex.	(B)	The	average	mass	spectra	for	
different	retention	times	at	T1:	20.4-20.8	min;	T2:	20.8-21.2	min;	T3:	21.2-
21.6	min.	(C)	Zoom-in	view	of	the	mass	spectrum	for	T2.	(D)	Elution	profile	for	
four	species	detected	by	SEC-MS.	 	
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Figure	5-4.	Online	SEC-denatured	MS	tested	with	the	AT-Arixtra	complex:	(A)	
UV	trace	(grey)	and	extracted	ion	profile	of	AT	(blue)	and	Arixtra	(orange)	
extracted	based	on	the	peaks	in	denatured	MS.	(B)	Average	mass	spectrum	
under	native	condition	(green)	and	denatured	condition	(blue)	within	the	
chromatogram	peak	at	T1	and	under	denatured	condition	with	the	
chromatogram	peak	at	T2	(orange).		 	
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Figure	5-S1.	Online	SEC-denatured	MS	of	BSA:	(A)	UV	and	BPC	traces	of	SEC	
chromatogram	of	BSA,	dimer	and	monomer	peaks	are	indicated	with	arrows;	
(B)	average	mass	spectra	of	BSA	dimer	(top)	and	monomer	(bottom)	under	
denatured	condition	(blue)	and	monomer	under	native	condition	(green).					
Table	5-1.	The	measured	mass	and	calculated	average	molecular	weight	at	
major	peaks	in	SEC-MS	of	AT•dp20	degraded	complex		 Unit:	Da	 (6,6,1)	 (8,9,1)	 (10,12,1)	measured	 1534.4	 2111.4	 2689.3	calculated	 1534.2	 2111.7	 2689.1			 	
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CHAPTER	6	
	
SUMMARY	AND	FUTURE	DIRECTIONS	
6.1	Summary	Heparinoid	 molecules	 bind	 to	 heparin-binding	 proteins	 through	 both	 the	long-distance	 electrostatic	 attraction	 between	 opposite	 charges	 and	 the	 short-distance	interactions	including	hydrogen	bonding	and	salt-bridge	bond.	Native	MS	is	an	excellent	 tool	 to	probe	 these	non-covalent	 interactions.	We	developed	multiple	strategies	 particularly	 for	 this	 system	based	 on	 the	 special	 properties	 of	 heparin-protein	 complexes.	 First,	 protein	 and	 heparin	 bind	 more	 tightly	 when	 they	 are	introduced	 to	 the	 gas	 phase,	 so	we	 can	 take	 advantage	 of	 the	 strong	 electrostatic	interaction	to	carry	out	 lossless	 ion	manipulations	 in	 the	gas	phase.	For	examples,	we	 selectively	 chopped	 off	 the	 unbound	 GAG	 component	 using	 collision-induced	activation	for	 identifying	the	number	of	saccharides	and	sulfate	groups	that	reside	on	 the	 binding	 interface	 (Chapter	 4);	 and	 we	 also	 performed	 limited	 charge	reduction	 to	 reconstruct	 the	mass	 and	 charge	 values	 for	 protein-heparin	 complex	ions	whose	binding	stoichiometry	does	not	change	during	reaction	with	the	electron	donors	 (Chapter	 2	 and	 3).	 Second,	 the	 structure	 of	 gaseous	 ions	 introduced	 by	native	electrospray	is	largely	similar	to	that	in	the	solution	and	allow	us	to	study	the	conformation	 of	 protein	 complex	 in	 the	 gas-phase	 using	 IM-MS.	 With	 CCS	measurement,	for	examples,	we	were	able	to	capture	a	near	native	structure	of	FGF-oligosaccharide	 complex	 and	 other	 two	 intermediate	 states	 created	 by	 collision-induced	 unfolding	 (Chapter	 4);	 and	 we	 also	 observed	 two	 distinct	 models	 for	
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protamine-oligosaccharide	 complexes	 (Chapter	 3)	 based	 on	 the	 charge-reduced	populations.	 Third,	 the	 presence	 of	 GAG	 chains	 brings	 about	 high	 degree	 of	heterogeneity	 in	 the	 complexes	 and	 it	 triggers	 the	 development	 of	 “top-down”	strategies	 to	 fetch	 the	 unique	 elements	 contributed	 to	 the	 binding	 affinity.	Technically,	 to	 reduce	 the	 heterogeneity,	 we	 built	 multiple	 two-dimensional	platforms	by	 incorporating	a	separation	 tool	with	MS	detection	such	as	quadruple	isolation	(Chapter	2	and	3),	online	chromatography	(Chapter	5)	and	ion-mobility	separation	(Chapter	2,3,4).	It	should	be	noted	that	all	strategies	we	describe	in	previous	chapters	are	not	limited	to	the	system	of	heparin-protein	complexes;	it	has	potential	to	be	applied	to	other	analytes	with	polydispersed	mass	distribution.	Online	SEC-MS	and	IXC-MS	are	powerful	 tools	 for	 quantitatively	 analysis	 of	 non-covalent	 protein-protein	complexes	 with	 multiple	 stoichiometries	 such	 as	 the	 complexes	 formed	 by	monoclonal	antibody	and	antigens	or	Fc	receptors.	Limited	charge	reduction	can	be	used	 for	 interpreting	 unresolved	 spectra	 (MS	 or	 IM-MS)	 of	 samples	 containing	proteins	 with	 heterogeneous	 modifications	 (e.g.	 antibody	 drug	 conjugation,	PEGylated	proteins).	Our	 results	 in	Chapter	2	 through	Chapter	5	provide	valuable	data	and	examples	showing	how	those	strategies	can	work	as	novel	solutions	to	the	heterogeneity-related	problems.	
6.2	Future	directions	Beyond	 my	 dissertation	 studies	 described	 in	 previous	 chapters,	 there	 are	three	 major	 directions	 we	 can	 explore	 in	 the	 future.	 Because	 CCS	 is	 an	 average	
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projection	 area	 of	 a	molecule	 at	 all	 orientations,	 it	 can	 reflect	 anisotropy	 to	 some	extent.	 As	 a	 result,	 the	 measured	 CCS	 values	 for	 a	 protein	 (e.g.	 FGF,	 AT	 and	protamine)	 in	 the	 presence	 of	 GAG	 chain	 are	 correlated	 to	 the	 structure	 of	 the	gaseous	ions.	However	the	specific	structure	of	a	protein	complex	is	still	not	clear.	In	future,	we	will	perform	molecular	dynamic	(MD)	programs	such	as	GROMAC,	VMD	to	 simulate	 the	 structures	 during	 protein	 aggregation	 or	 protein	 unfolding	 under	collisional	 activation	 over	 a	 period	 of	 time.	We	will	 also	 extract	 CCS	 values	 from	several	 snapshots	 obtained	 from	 MD	 and	 find	 the	 one	 that	 is	 closest	 to	 the	experimental	CCS.	This	approach	can	eventually	help	us	to	understand	what	domain	of	 FGF	 is	 unfolded	 in	 the	partially	 activated	 state	 and	 to	 confirm	 that	 the	 binding	interface	is	not	damaged	in	this	state.	In	 Chapter	 4	 and	 5,	 we	 only	 focus	 on	 identifying	 the	 binding	 motif	 on	heparinoid	chain.	We	are	also	interested	in	mapping	the	heparin-binding	epitope	on	the	 protein	 using	 MS-based	 footprinting	 such	 as	 hydrogen/deuterium	 exchange	(HDX),	 covalent	 labeling	 or	 cross-linking.	 HDX-MS	 has	 been	 a	 well-established	technique	to	probe	the	protein-ligand	interface	assuming	the	ligand	can	change	the	solvent-exposed	 surface	 of	 the	protein.	We	hypothesize	 that	 the	 region	of	 protein	that	binds	to	heparin	is	less	solvent-exposed	in	the	presence	of	heparin	and	shows	a	lower	deuterium	uptake.	This	 approach	has	never	been	 reported	by	others	 so	we	can	test	it	with	well-studied	heparin-binding	proteins	such	as	FGF	and	AT.	At	 last,	as	shown	in	Chapter	5,	 the	degradation	of	heparin	using	heparinase	allows	 us	 to	 generate	 the	minimal	 segment	 of	 GAG	 that	 is	 bound	 to	 AT.	We	 also	demonstrate	 that	 analyzing	 the	 saccharide	 units	 dissociated	 from	 the	 complex	
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through	 protein	 denaturation	 can	 achieve	 better	 mass	 accuracy	 compared	 to	analyzing	the	mass	of	AT•GAG	complex	using	native	MS;	the	 latter	requires	higher	mass	range	and	more	delicate	desolvation	condition.	 In	 future,	we	will	develop	an	approach	 to	achieve	 this	goal	with	higher	controllability.	First,	we	will	 immobilize	the	protein	on	beads	and	pack	them	into	a	preparation	column.	Then	we	will	load	a	mixture	of	heparinoid	molecules	 and	wash	with	 the	equilibration	buffer.	Next,	we	will	wash	 the	 column	with	 the	 solution	 containing	proper	 concentration	of	 salt	 to	get	 rid	 of	 the	 nonspecifically	 bound	 species.	 Heparinase	 digestion	 step	 will	 be	carried	out	by	directly	 injecting	 the	enzyme	 into	 the	column	and	 leave	at	33°C	 for	adequate	 time.	 Then	 we	 will	 wash	 out	 the	 degraded	 unbound	 products	 with	 the	washing	buffer	and	elute	the	tightly	bound	species	by	increasing	the	concentration	of	 salt	 in	 the	mobile	phase.	The	eluted	 fraction	can	be	analyzed	using	FT-MS	after	desalting	and	 lyophilizing	 the	 sample.	We	can	 test	 this	 approach	with	AT	because	immobilized	 AT	 is	 a	 matured	 technique	 for	 screening	 heparin	 fraction	 with	 high	anticoagulant	 effect.	 The	 in-column	 digestion	 is	 also	 a	 routine	 approach	 that	 has	been	 performed	 in	 the	 process	 of	 GST-fusion	 protein	 purification.	 Therefore	 we	assume	that	this	approach	we	propose	here	is	feasible	and	may	give	us	some	results	with	higher	accuracy	and	less	bias.			 	
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APPENDIX	
	
CCS	CALIBRATION	CURVES	CCS	calibration	was	carried	out	 following	the	standard	protocol	 that	can	be	found	 in	 Nature	 Protocols	 3,	 1139	 -	 1152	 (2008).	 The	 curves	 are	 plotted	 using	reported	CCS	of	standard	proteins	(y-axis)	vs.	the	corrected	drift	time	measured	in	the	experimental	condition	(t”,	x-axis).		Standard	 proteins	 were	 selected	 based	 on	 the	 required	mass	 range	 of	 the	sample	 to	 be	 analyzed.	 For	 the	 protamine-do20	 experiment	 (see	 Chapter3),	 the	standard	 proteins	 are	 Cytochrome	 C	 and	 monomeric	 β-Lactoglobulin.	 For	 the	FGF•dp5/dp10	 experiments	 the	 standard	 proteins	 are	 Cytochrome	 C,	 β-Lactoglobulin,	 BSA	 and	 ADH.	 All	 standard	 proteins	 were	 analysis	 under	 native	conditions.	
		
Figure	APPX-1.	CCS	calibration	curves	for	protamine-dp20	experiment		 	
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Figure	APPX-2.	CCS	calibration	curves	for	FGF•dp10	complex			 	
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